Formulation and In Vitro Evaluation of Mexiletine Hydrochloride Timed Release Capsules by Chandrasekaran, B
“FORMULATION AND IN VITRO EVALUATION OF MEXILETINE HYDROCHLORIDE TIMED RELEASE 
CAPSULES 
 
 
 
261210802 
Chapter 1 Introduction 
Department of pharmaceutics  1 JKKMMRF college of pharmacy 
 
INTRODUCTION 
1.1 Oral drug delivery 
Most convenient oral drug products such as tablets and capsule are 
formulated to release the active drug immediately after oral administration to obtain 
rapid and complete systemic drug absorption. Such immediate release products 
result in relatively rapid absorption and onset of accompanying pharmacodynamic 
effects. However, after absorption of the drug from the dosage form is complete, 
plasma drug concentrations decline according to the drugs pharmacokinetic profile. 
Eventually, plasma drug concentrations fall below the minimum effective plasma 
concentration (MEC), resulting in loss of therapeutic activity. Before this point is 
reached, another dose is usually given if a sustained therapeutic effect is desired. An 
alternative to administering another dose is to use a dosage form that will provide 
sustained drug release, and therefore maintain plasma drug concentrations, beyond 
what is typically seen using immediate- release dosage form. (Leon shargel et al, 
2004). 
  The term modified – release drug product is used to describe products that 
alter the timing and/or the rate of release of the drug substance. A modified-release 
dosage form is define “ as one for which the drug – release characteristics of time 
course and/or location are chosen to accomplish therapeutic or convenience 
objectives not offered by conventional dosage forms such as solution, ointments, or 
promptly dissolving dosage forms as presently recognized”. Several types of 
modified-release drug products are recognized: 
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• Extended- release drug products: A dosage form that allows at least a 
twofold reduction in dosage frequency as compared to that drug presented as 
an immediate-release (conventional) dosage forms include controlled-
release, sustained-release and long-acting drug products. 
• Delayed-release drug products. A dosage form that releases a discrete portion 
of drug, at a time or at times other than promptly after administration, 
although one portion may be released promptly after administration. Enteric- 
coated dosage forms are the most common delayed-release products. 
• Targeted-release drug products. A dosage forms that release drug at or near 
the intended physiologic site of action. Targeted-release dosage forms may 
have either immediate or extended-release characteristics. 
1.2: Selection of Drug Candidate for Timed Release Dosage Forms 
The physico – chemical properties of the drug such as pKa, partition 
coefficient, Biological half life, molecular weight, dose of the drug etc., have to be 
considered before selection. (Leon Lachman 1987). 
Characteristics of drugs suitable for formulation as Timed Release Products 
• Exhibit moderate rates of absorption and excretion. 
• Uniform absorption throughout the gastrointestinal tract. 
• Administered in relatively small doses. 
• Possess good margin of safety. 
• Used for treatment of chronic therapy. 
Characteristics of drug unsuitable for formulation as Sustained Release Products 
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• Not effectively absorbed in the lower intestine (Riboflavin) 
• Absorbed and excreted rapidly i.e. short biological half lives, less than one 
hour (Penicillin G, Furosemide). 
• Long biological half lives greater than 12 hours (Diazepam, Phenytoin) 
• Large doses required, (Sulphonamides) 
• Drugs with low therapeutic index (Sulphonamides) 
• No clear advantage for sustained release formulation (Griseofulvin) 
1.3: Types of Oral Controlled Release Drug Delivery Systems 
 A number of techniques are used to achieve controlled release of drugs via 
the oral cavity. The majority of the oral controlled release systems relay on 
dissolution, diffusion or a combination of both mechanisms to generate slow release 
of drug. 
• Dissolution controlled release systems 
• Diffusion controlled release system 
• Diffusion and dissolution system 
• Osmotically controlled release system 
• Gastroretentive drug delivery system 
• Electrically stimulated release devices 
• Ion-exchange resins 
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1.3.1: Dissolution Controlled Release Systems 
 A drug with a slow dissolution rate will sustain release rate of the drug from 
the dosage form. Here the rate-limiting step is dissolution. This being true, sustained 
release preparation of drug could be made by decreasing their rate of dissolution. 
Dissolution controlled systems can be made either by 
o Varying concentration of rate controlling coats or polymers (Matrix 
Dissolution Systems) 
o By administering the drug as a group of beads that have coating of 
different thickness (Encapsulated Dissolution Systems) 
Matrix Dissolution Systems are prepared by compressing the tablet with a 
slowly soluble polymer carrier into tablet form. Wax matrices are prepared either by 
congealing or dispersion the drug – wax mixture in water. 
 Encapsulated Dissolution Systems contain beads that have different coating 
thickness, their release will occur in a progressive manner. Those with the thinnest 
layer will provide the initial dose and the maintenance of drug levels at later times 
will be achieved from those with thicker coating. This dissolution process at steady 
state is described by the Noyes-Whitney equation. (Gilbert S. Banker et al, 2002). 
  dc/dt kD(CS-C) = DA/h (CS-C) 
Where 
dc/dt = dissolution rate. 
kD             = dissolution rate constant. 
D           = Diffusion coefficient. 
CS  = Saturation solubility of solid. 
C  = Concentration of solute in the bulk solution 
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1.3.2: Diffusion Controlled Release Systems 
 In these systems the release rate of drug is determined by its diffusion 
through a water insoluble polymer. There are basically two types of diffusion 
devices. (Gilbert S. Banker et al, 2002). 
1.3.2.1: Reservoir Devices: 
 Reservoir devices are characterized by a core of drug, the reservoir, 
surrounded by a polymeric membrane. The nature of the membrane determines the 
rate of release of drug. The methods used to develop reservoir type devices include 
micro-encapsulation of drug particles and coating of tablet containing drug cores. 
Advantage: 
i) These devices can offer zero-order release of the drug. 
ii) Avoid patient compliance problem. 
iii) Employ less total drug. 
Disadvantage: 
i) System must be physically removed from implant sites. 
ii) Difficult to deliver high molecular weight compounds. 
1.3.2.2: Matrix Device 
 The three major types of materials used in the preparation of matrix devices 
are insoluble plastics, hydrophilic polymers and fatty compounds. The most 
common method of preparation is to mix the drug with the matrix material and then 
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compress the mixture. The drug release from a porous or granular matrix can be 
described by 
                M= (Ds.Ca.{P/T}.[2C0-PCa]t)1/2 
Where 
               P   =   Porosity of the matrix 
               T   =   Tortuosity 
              Ca   =   Solubility of the drug in the release medium 
               DS  =   Diffusion coefficient in the release medium 
1.3.3.Diffusion and Dissolution Controlled Systems 
 In these systems the release rate of drug is determined by both the diffusion 
and dissolution mechanisms. The drug core is encased in partially soluble 
membrane. Pores are thus created due to dissolution of parts e membrane which 
permit entry of aqueous medium into the core and hence drug dissolution and allow 
diffusion of dissolved drug out of the system. (Gilbert S. Bakers et al, 2002). 
1.3.4. Osmotically Controlled Release Systems 
 The osmotic pump represents a newer concept in extended-release 
preparations. Drug delivery is controlled by the use of an osmotically controlled 
device that promotes a constant amount of water into the system, either by 
dissolving and releasing a constant amount of drug per unit time or by the use of a 
“push-pull” system that pushes the drug out at a constant rate as water flows into an 
expandable osmotic compartment. Drug is release via a single laser-drilled hole in 
the tablet. 
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 A representative osmotic oral drug product is the “push-pull” system called 
Gastro intestinal Therapeutic System (GITS), developed by Alza Corporation for 
nifedipine (Procardia XL) and other drugs. The system consists of a semi permeable 
membrane and a two-layer core of osmotic ingredient and active drug. As water 
enters the system, the osmotic pressure builds up from the inner layer, pushing the 
drug out through a laser-drilled orifice in the drug layer. (Leon Shargel et al, 2004). 
1.3.5: Gastro retentive Drug Delivery Systems 
 Dosage forms that can be retained in stomach are called Gastro retentive 
Drug Delivery System (GEDDS). GRDDS can improve the controlled delivery of 
drugs that have an absorption window by continuously releasing the drug for a 
prolonged period of time before it reaches its absorption site thus ensuring its 
optimal bioavailability. 
 The approaches that have been pursued to increase the retention of an oral 
dosage form in the stomach include Bioadhesive systems, swelling and expanding 
systems, High density systems and Low density (Floating) systems. 
1.3.5.1: Bioadhesive Systems 
 Bioadhesion is the process whereby synthetic and natural macromolecules 
adhere to the biological membranes in the body and remain there for an extended 
period of time. If the membrane substrate is mucosal layer then the process is 
referred to as mucoadhesion. The bioadhesives increase the residence time and 
contact time at the area of absorption and provide a high concentration gradient 
across the membrane. 
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1.3.5.2: Swelling and Expanding Systems 
 These system increases the residence time of the dosage form in the stomach. 
Particles greater than 10mm are unable to enter the duodenum and are retained in the 
stomach. The swelling systems incorporate hydrogels which are polymers that can 
swell up to 100 times their dry weight. The hydrogels used must be biodegradable. 
1.3.5.3: High Density Systems 
           In high density system the bulk density of the dosage form must exceed that 
of normal stomach and should be at least 1.40. In preparing such formulations, drug 
can be coated on a core with heavy, inert material such as barium sulfate and 
titanium dioxide. The weighed pellet can then be covered with a diffusion controlled 
membrane. 
1.3.5.4: Low Density (Floating) Systems 
Floating drug delivery system (FDDS) have a bulk density less then gastric 
fluids and so remain buoyant in the stomach without affecting the gastric emptying 
rate for a prolonged period of time. While the system in floating on the gastric 
contents, the drug is released slowly at the desired rate from the system. After 
release of drug, the residual system in emptied from the stomach. This results in an 
increased GRT and a better control of fluctuations in plasma drug concentration. 
These systems are suitable for drugs that are poorly soluble or unstable in the 
intestinal medium. 
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1.3.6: Electrically Stimulated Release Devices 
 These are monolithic devices prepared by using polyelectrolyte gels which 
swell when an external electrical stimulus is applied, causing a change in PH. The 
release could be modulated, by the current, giving a pulsatile release profile. Precise 
control over the release of drug from devices implanted in the body, such as 
quantity, timing, is highly desirable in order to optimize drug therapy. Electrically-
controllable drug release from polyelectrolyte hydrogels is helpful in achieving these 
goals. 
 The mechanism of drug release include ejection of the drug from the gel as 
the fluid phase synereses out, drug diffusion along a concentration gradient, 
electrophoresis of charged drugs towards and oppositely charged electrode and 
liberation of the entrapped drug as the gel complex erodes. 
1.3.7: Ion-Exchange Resins 
 Ion exchange systems use resins composed of water insoluble cross linked 
polymers. These polymers contain salt-forming functional groups in repeating 
positions on the polymer chain. The drug is bound to the resin and released by 
exchanging with appropriately charged ions in contact with the ion-exchange 
groups.  
  Resin+ - Drug--  + X--    Resin+  -  X--   + Drug— 
  Resin-- - Drug+  + Y+    Resin--  -  Y+   + Drug+ 
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 Where X-- and Y+ are ions in the GI tract. The free drug then diffuses out of 
the resin. The drug-resin complex is prepared either by repeated exposure of the 
resin to the drug in a chromatography column or by prolonged contact in solution. 
 The rate of drug diffusing out of the resin in controlled by the area of 
diffusion, diffusional path length and rigidity of the resin, which is a function of the 
amount of cross-linking agent used to prepare the resin. An improvement in this 
system is to coat the Ion-exchange resin with a hydrophobic rate-limiting polymer, 
such as ethyl cellulose or wax. These systems rely on the polymer coat to govern the 
rate of drug availability. (Gilbert S.Banker et al) 2002. 
1.4. Factors influencing the design and performance of Timed release products 
The design of controlled - release delivery system is subjected to several 
variables of considerable importance. Among these, the properties of the drug, the 
route of drug delivery, and the disease being treated and length of the therapy have 
major importance. 
1.4.1. Physicochemical factors 
•    Aqueous solubility 
•    Partition coefficient 
•    Drug stability 
•    Protein binding 
•    Molecular size and Difrusivity  
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1.4.2. Biological factors 
•    Absorption 
•    Distribution 
•    Elimination 
•    Biological half life and Duration of action 
•    Side effects and Margin of safety 
•    Dose size 
•    Disease state 
1.4.3. Physicochemical factors 
•    Aqueous solubility: 
The aqueous solubility of a drug influences its dissolution rate, which in turn 
establishes its concentration in solution and hence the driving force for diffusion 
across membrane. The choice of mechanism for oral Timed release systems is 
limited by aqueous solubility of the drug. Diffusional systems will be poor choices 
for slightly soluble drugs since the driving force for diffusion; the concentration in 
aqueous solution will be low. Such drugs may be effectively incorporated in matrix 
system. 
•    Partition coefficient: 
Partition coefficient (K0/W) is defined as the ratio of the fraction of the drug 
in an oil phase to that of an adjacent aqueous phase. 
K=Co/Cw 
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Where 
Co = Equilibrium concentration of all forms of the drug e.g. ionized and unionized 
in an organic phase at equilibrium 
Cw= Equilibrium concentration of all forms in aqueous phase 
Accordingly, compounds with a relatively high K0/w are predominantly 
lipicl-soluble and consequently, have very low aqueous solubility. Furthermore, 
these compounds can usually persist in the body for long periods as they can localize 
in the lipid membranes of cells, (e.g.: Phenothiazines). Compounds with very low 
K0/wwill have difficulty in penetrating membranes, resulting in poor bioavailability. 
Furthermore, partitioning effects apply equally to diffusion through polymer 
membranes. The choice of diffusion-limiting membranes must largely depend on 
partitioning characteristics of the drug. Drugs with a partition coefficient that is 
higher or lower than the optimum (i.e., 1000/1) in general, are poor candidates for 
formulation into Timed dosage forms, 
•    Drug stability 
Orally administered drugs can be subject to both acid base hydrolysis and 
enzymatic degradation. For drugs like Propantheline that are unstable in the 
stomach, the most appropriate controlling unit would be the one that releases its 
contents only in the intestine. The reverse in the case for drugs like Probanthine that 
are unstable in the environment of the intestine, the most appropriate controlling unit 
in this case would be one that releases its contents only in the stomach. In general, 
drugs with significant stability problems in any particular area of the gastrointestinal 
tract are less suitable for formulation into Timed release systems. 
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•    Protein binding: 
Many drugs bind to plasma proteins with a significant influence on the 
duration of drug action. If a drug has binding properties with a particular protein, 
then the distribution of the drug into the extra vascular space is governed by the 
equilibrium process of dissociation of the drug from the protein. The drug-protein 
complex can serve therefore as a reservoir in the vascular space for controlled drug 
release to extra vascular tissues, but only for those drugs that exhibit a high degree 
of binding. Extensive binding to plasma proteins will be evidenced by a long half-
life of elimination for the drug and such drugs generally do not require a Timed 
release dosage form. 
•     Molecular size and Diffusivity: 
Drugs in most of the Timed release systems must diffuse through a rate 
controlling membrane or matrix. The ability of a drug to diffuse through these 
membranes is known as diffusivity (diffusion coefficient). This diffusivity is a 
function of its molecular size (or molecular weight) and is related by the equation. 
Log D = Svlogv+Kv = SmlogM + Km 
Where 
D = diffusivity 
M = molecular weight 
V = molecular volume 
Sv, Sm, Kv and Km = constants in a particular system. 
In general the denser the medium, the smaller is the diffusivity.  
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1.4.4. Biological factors 
The design of sustained release products should be based on a 
comprehensive picture of drug disposition. This would entail a complete 
examination of the ADME characteristics of a drug following multiple dosing. 
Absorption: 
The rate, extent and uniformity of absoiption of a drug are important factors 
when considering it's formulation into a sustained release dosage form. To maintain 
a constant blood or tissue level of drug, it must be uniformly released from the 
sustained release system and then uniformly absorbed. Since the rate-limiting step in 
drug delivery from a sustained release product is its release from a dosage form, a 
rapid rate of absorption of drug relative to its release is essential if the system is to 
be successful. In case of sustained release dosage form, the rate constant for drug 
release is much less than the constant for drug absorption (i.e., Kr<«Ka). Assuming 
that the transit time of a drug through the absorption area of the gastro intestinal tract 
is between 9 and 12 hrs, the maximum absorption half-life should be 3 to 4 hrs. This 
corresponds to a minimum absorption rate constant K.a of 0.17 to 0.23 hr" necessary 
for about 80 to 95 % absorption over a 9 to 12 hr transit time. For a drug with a very 
rapid rate of absorption (i.e., K,a» 0.23 hr"1), the above discussion implies that a first 
order release rate constant Kr < 0.17 hr'1 is likely to result in unacceptably poor 
bioavailability in many patients. Therefore, slowly absorbed drugs will be difficult 
to formulate into Timed release dosage forms. 
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Distribution: 
Two parameters that are used to describe the distribution characteristics of a 
drug are its apparent volume of distribution (V,j) and the ratio of drug concentration 
in the tissue to that in plasma (T/P ratio) at the steady state. In general, the bound 
portion of drug can be considered inactive and unable to cross membranes. At high 
binding one sees prolonged drug action. The apparent volume of distribution of a 
drug is frequently used to describe the magnitude of distribution, including binding, 
within the body. The total apparent volume of distribution for a drug at steady state 
can be calculated from the following equation. 
Vdss=[(kl2+k21)/k2l]Vp 
Where, 
Vdss is the apparent volume of distribution at steady state and FC2i are the 
constants for the distribution of drug from the central to peripheral compartment and 
from peripheral to central compartments respectively. 
Vp is the volume of central compartment.  
Elimination: 
Elimination of a drug involves two aspects i.e., metabolism and excretion. 
Metabolism of a drug can either inactivate an active drug or convert an inactive drug 
to an active metabolite. Drugs that are significantly metabolized before absorption, 
either in the lumen or tissue of the intestine, can show decreased bioavailability 
particularly from slowly releasing dosage forms. Metabolism of a drug will be 
reflected in the elimination rate constant of a drug or by the appearance of a 
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metabolite. It is possible to incorporate this pharmacokinetic property into the design 
of sustained release product, provided that the rate and extent of metabolism are 
predictable and that the rate constant(s) for the process are not too large. 
Undoubtedly, complex metabolic patterns would make the design much more 
difficult, particularly when biological activity is wholly or partly due to a metabolite, 
as is the case of Isosorbide 2,5-dinitrate. 
Biological half life and Duration of action: 
The usual goal of an oral Timed release product is to maintain therapeutic 
blood levels over an extended period. The elimination rate is quantitatively 
described by the half-life. The biological half-life and hence duration of action of a 
drug obviously play a major role in the process of considering a drug for sustained 
release. Therapeutic compounds with a short half-life are excellent candidates for 
sustained-release preparations, since this can reduce dosage frequency. However, 
this is limited, in that drugs with very short biological half life as it may require 
excessively large amounts of drug in each dosage unit to maintain sustained effect. 
In general, drugs with half-life shorter than two hours are poor candidates for 
sustained release preparations. Drugs with long half-life, more than 8 hrs, are also 
generally not used in sustaining forms, since their effect is already sustained. 
Side effects and Margin of safety: 
Theoretically, the incidence of side effects can be minimized by controlling 
the concentration at which the drug exists in plasma at any given time, and hence 
controlled release formulations appear to offer a solution to this problem. By 
slowing the rate at which the drugs are released, the chances of gastrointestinal 
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irritation will be reduced due to a smaller amount of drug exposed to the 
gastrointestinal mucosa at the given time. The most widely used measure of the 
margin of safety of a drug is its therapeutic index (TI). 
= TD50/ED50 
Where, 
= median toxic dose = median effective dose  
Drugs with very small value of therapeutic index usually are poor candidates 
as sustained release products. 
Dose Size: 
For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general a single dose of 0.5 to Igm is considered 
maximum for conventional dosage form. This also holds for Timed release dosage 
forms. 
Disease State: 
Sometimes the disease states are considered before the designing of an oral 
SR dosage form. This can be explained by taking the example of Aspirin (for 
rheumatic arthritis) which is not a suitable candidate for Timed release dosage form. 
Still an aspirin sustained release dosage form could be advantageous to maintain 
therapeutic concentrations, particularly throughout the night, thus alleviating 
morning stiffness. 
 
Chapter 1 Introduction 
Department of pharmaceutics  18 JKKMMRF college of pharmacy 
 
1.5. TIMED-RELEASED DRUG DELIVERY: 
             Timed-release dosage forms are designed to achieve a prolonged therapeutic 
effect by continuously releasing medication over an extended period of time after 
administration of a single dose.  The basic intention of any drug delivery system is 
to provide a therapeutic amount of drug to proper site in the body of promptly 
achieve and then maintain the desired drug concentration.  Extended release dosage 
form that shows at least a twofold reduction dosage form and various example of 
extended release dosage forms included controlled-release, sustained-release, and 
long acting drug product and different types of extended release products include 
drug release from matrix, gum-type matrix tablets, polymeric matrix tablet, ion-
exchange, core tablets, microencapsulation, osmotic extended release etc.(shargel, 
2005). 
Oral administration has been known from decades as the most widely used 
route of drug administration amongst all routes that have been explored for the 
systemic delivery of drugs via various pharmaceutical products of different dosage 
forms (chein 1992). In the recent years, scientific and technological advancement 
have been made in research and development of rate controlled oral drug delivery 
system by overcoming various physiological constraints, such as short residence 
time and unpredictable gastric emptying time (Forman et al, 1994). Pulsatile drug 
delivery and timed-release drug delivery are among such advances. There are many 
drugs that are more effective when given to the patient in a pulsatile manner as 
opposed to a continuous release fashion. 
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Traditionally, drug delivery has meant in getting a simple chemical absorbed 
predictably from the gut or from the site of injection. A second-generation drug 
delivery goal has been the perfection of continuous, constant rate delivery of 
bioactive agents.  However, living organisms are not ‘’’’zero-order”” in their 
requirement or response to drugs.  They are predictable resonating dynamic systems, 
which require different amounts of drug at predictably different times within the 
circadian cycle which will maximize desired therapeutic effects and minimize 
undesired drug effects. (survase S, kumar N2007) 
In case of chronic treatment, where the drug is given in sustained release 
dosage form, continuous exposure of the drug to body may lead to adverse effect. 
(drugbank 2005). 
1.5.1. Advantages of timed-release drug delivery: 
 Prolonged administration of therapeutic dose at the desired delivery rate. 
 Avoid patient compliance problem. 
 Employ less total drug. 
 Obtain less potentiating/reduction in drug activity with chronic use. 
 Minimize drug accumulation with chronic dosing. 
 Improve efficiency of treatment. 
 Improve control of condition, i.e., reduce fluctuation in drug level. 
 Increased safety margin of high potency drugs due to control of plasma 
levels.(Brahmankar DM and Jaiswal SB 2000). 
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1.5.2 Disadvantages of timed-release drug delivery: 
 Decreased systemic availability in comparison to immediate release 
conventional dosage forms; this may due to incomplete release, increased 
first pass metabolism, increased instability, insufficient residence time for 
complete release, site-specific absorption, pH dependent solubility. 
 Poor in-vitro-in-vivo correlation. 
 Possibility of dose dumping due to food interaction. 
 Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions. 
 Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths. 
 Higher cost of formulation. 
Mexiletine hydrochloride is an anti-arrhythmic agent, used for ventricular 
arrhythmia.  A marketed product of this drug is given in capsule form thrice a day. 
Hence, a timed-release dosage form of mexiletine hydrochloride has been 
investigated to deliver the doses at different time intervals in a pulsatile manner.  
Instead of taking three doses at three different time intervals per day, the patient will 
have to take one timed release capsule leading to better patient compliance. 
1.6. Introduction to the arrhythmias: 
          The arrhythmias are conceptually simple dysfunctions cause abnormalities in   
impulse formation and conduction in the myocardium.  However, in the clinic, 
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arrhythmias present as a complex family of disorders that a show a variety of 
symptoms.  For example, cardiac arrhythmias may cause the heart,(maryet.al,2000) 
1. To beat too slowly (sinus bradycardia.) 
2. To beat too rapidly (sinus or ventricular tachycardia, atria or ventricular 
premature depolarization). 
3. To respond to impulses originating from sites other than a SA node. 
4. To respond to impulses travelling along accessory pathways that lead to deviant 
depolarization. 
In order to make sense of this large group of disorders, it is useful to 
organize the arrhythmias into groups according to the anatomic site of the 
abnormality-the atria, AV node, or the ventricles. 
Causes of Arrhythmias 
Most arrhythmias arise either from aberrations in impulse generation or from 
a defect in impulse conduction. 
Abnormal automaticity 
           The SA node shows the fastest rate of Phase 4 depolarization and therefore, 
exhibits a higher rate of discharge than that occurring in other pacemaker cells 
exhibiting automaticity.  The SA node thus normally sets the pace of contraction for 
the myocardium, and latest pacemakers are depolarized by impulses coming from 
the SA node.  However, if cardiac sites other than the SA node show enhanced 
automaticity, they may generate competing stimuli, and arrhythmias may arise.  
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Abnormal automaticity may also occur if the myocardial cells are damaged, for 
example, by hypoxia or potassium imbalance.  These cells may remain partially 
depolarized during diastole and therefore can reach the firing threshold earlier than 
normal cells.  Abnormal automatic discharges may thus induce arrhythmias. 
Effect of drugs on automaticity 
Most of the anti-arrhythmic agents suppress automaticity by decreasing the 
slope of Phase 4 depolarization and or by raising the threshold of discharge to a less 
negative voltage.  Such drugs cause the frequency of discharge to decrease, an effect 
that is more pronounced in cells with ectopic pacemaker activity than in normal 
cells. 
Abnormalities in impulse conduction 
          Impulses from higher pacemaker centers are normally conducted down 
pathways that bifurcate to activate the entire ventricular surface.  A phenomenon 
called re-entry can occur if a unidirectional block caused by myocardial injury or 
prolonged refractory period results in an abnormal conduction pathway.  Re-entry is 
the most common cause of arrhythmias and can occur at any level of the cardiac 
conduction system.  For example consider a single purkinje fiber with two 
conduction pathways to ventricular muscle.  An impulse normally travels down 
limbs of the conduction path.  However, if myocardial injury results in a 
unidirectional block, the impulse may only be conducted down pathway.  If the 
block in pathway is in the forward direction only, the impulse may travel in a 
retrograde fashion through pathway and re-enter the point of bifurcation.  This short-
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circuits pathway results in reexcitation of the ventricular muscle, causing premature 
contraction or sustained ventricular arrhythmia. 
Effects of drugs conduction abnormalities: 
Anti-arrhythmic agents prevent re-entry by slowing conduction and or 
increasing the refractory period required to convert a unidirectional block into a 
bidirectional block. 
Classifications of 0 phase anti-arrhythmic agents:  
1) Membrane stabilizing agents (Na+ channel blockers) 
     Moderately decrease dv/dt of 0 phase – 
                        Quinidine, Procainamide. 
     Little decrease in dv/dt of 0 phase – 
                        Lidocaine, Mexiletine HC1. 
     Marked decrease in dv/dt of 0 phase – 
                        Propafenone, Flecainide. 
2) Antiadrenergic agents (beta blockers) – 
                        Propranolol, Esmolol. 
3) Agents widening AP – 
                       Amiodarone, Bretylium, Dofetilide 
4) Calcium channel blockers –  
                      Verampil, Dilitazem 
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Mexiletine hydrochloride comes under the class of membrane stabilizing 
agents and used as an anti-arrhythmic agent for decreasing ventricular arrhythmia’s 
and belongs to chemical class of di methyl benzene derivatives.(Tripati KD 2006). 
1.7. Classification of  Pulsatile drug delivery system: 
Pulsatile drug delivery system can be classified as site-specific and time-
controlled systems. Drug release from site-specific systems depends on the 
environment in the gastro intestinal tract, e.g., on pH, presence of enzymes, and the 
pressure in the gastrointestinal tract. In contrast, time-controlled DDS are 
independent of the biological environment. The drug release is controlled only by 
the system.  Time-controlled pulsatile delivery has been achieved mainly with drug-
containing cores, which are covered with release-controlling layers. (Gathoskaret.al, 
2004, Shivakumar et.al,2003) 
                                                         Pulsatile drug delivery system 
 
Single unit system 
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E.g. Time clocksystem 
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                                Fig 1.  Classification of pulsatile drug delivery 
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Traditionally, drug delivery has meant getting a simple chemical absorbed 
predictably from the gut or from the site of injection.  A second-generation drug 
delivery has been the perfection of continuous, constant rate delivery of bioactive 
agents. However, living organisms are not “zero-order” in their requirement or 
response to drugs.  They are predictable resonating dynamic systems, which require 
different amounts of drug at predictably different times within the circadian cycle 
which will maximize desired and minimize undesired drug effects.(Youan B 
2004)Till early 1990s efforts have been made to design the drug delivery system 
which will release the drug at fairly constant rate. 
In fact these systems turned to be one of the most successful systems in 
delivering the drug molecule.(Maroni et.al,2005) but still for many of the drugs, use 
of such systems is not suitable because of a number of reasons.  This is particularly 
true in cases where the drug is subjected to large metabolic degradation.  Due to 
‘first pass effect’ there will be reduction in the bioavailability of the drug because 
gradual release can result in greater degradation.  Secondly drugs with short half-life 
need to be administered repeatedly which results in patient non-compliance.  
Further, in case of chronic treatment, where the drug is given in sustained release 
dosage form, continuous exposure of the drug to body may lead to adverse effect.  
Lastly, drugs which exhibit tolerance should not be delivered at a constant rate, since 
the drug effect decreases with time at constant drug level.  In addition drug toxicity 
increases with time when drug levels are held constant.  In such cases it is preferable 
to choose a dosage form which will provide desired concentration of drug at 
particular time point only. (Pozzi et.al,2005) 
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Now a days, concept of chronopharmaceutics has emerged, wherein, 
research is devoted to the design and evaluation of drug delivery systems that release 
a therapeutic agent at a rhythm that ideally matches the biological requirement of a 
given disease therapy.  Diseases where a constant drug levels are not preferred, but 
needs a pulse of therapeutic concentration in a periodic manner acts as a push for the 
development of “Pulsatile Drug Delivery Systems”. (Siegel RA and Pitt CG 1995). 
In these systems, there is rapid and transient release of a certain amount of 
drug molecules within a short time-period immediately after a predetermined off 
release period.  Various techniques are available for the pulsatile delivery like pH 
dependent systems, time dependent systems, micro-flora activated systems, etc. 
which can be designed as per the physiology of disease and properties of the drug 
molecule.  The focus of the present review is primarily on the pulsatile drug delivery 
methodologies and the upcoming technologies, which are being exploited on an 
industrial scale. 
1.7.1 Methodologies for Pulsatile drug delivery 
Methodologies for the pulsatile drug delivery system can be broadly 
classified into three classes, 
1. Time controlled 
2. Stimuli induced 
3. Externally regulated 
In time controlled drug delivery systems pulsatile release is obtained after a 
specific time interval in order to mimic the circadian rhythm.  Such type of pulsatile 
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drug delivery system contains two components: one is immediate release type and 
other one is a pulsed release type.  
In these systems there is release of the drug after stimulation by any 
biological factor like temperature, or any other chemical stimuli.  These systems are 
further classified into temperature induced systems and chemical stimuli induced 
system, on the basis of stimulus. 
In these systems there is a release of the drug after externally controlled 
device like an automatic motor or remote oriented control. By an externally fixed 
device we can control the release of a device and its action. 
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2.  REVIEW OF LITERATURE 
Hyun Seok Hwang et al, (2011) had found that Inhibition of cardiac calcium 
release channels determines efficacy of class I Antiaarrhythmic drugs in 
catecholaminergic polymorphic ventricular tachycardia.  Catecholaminergic 
polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac 
ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat. The 
class Ic antiarrhythmic drug flecainide blocks RyR2 channels and prevents CPVT in 
mice and human.  They first measured the effect of all class I antiarrhythmic drugs 
marketed in the United States (quinidine, procainamide, disopyramide, lidocaine, 
mexiletine, flecainide, and propafenone) on single RyR2 channels incorporated into 
lipid bilayers. Only flecainide and propafenone inhibited RyR2 channels, with the S-
enantiomer of propafenone having a significantly lower potency than R-propafenone 
or flecainide. In Casq2−/− myocytes, the propafenone enantiomers and flecainide 
significantly reduced arrhythmogenic Ca2+ waves at clinically relevant 
concentrations, whereas Na+ channel inhibitors without RyR2 blocking properties 
did not.RyR2 cardiac Ca2+ release channel inhibition appears to determine efficacy 
of class I drugs for the prevention of CPVT in Casq2−/− mice. Propafenone may be 
an alternative to flecainide for CPVT patients symptomatic on β-blockers. 
Xiaoxiong Wei et al., (1999)  The objectives of this study were to characterize the 
inhibitory effects of mexiletine, lidocaine, and tocainide on cytochrome P-450 1A2 
(CYP1A2) activity in human liver microsomes and to evaluate their relative 
inhibitory potencies by using a molecular model of this P-450 isozyme. The 
inhibitory effect of mexiletine, lidocaine, and tocainide on cytochrome CYP1A2 in 
human liver microsomes was examined with methoxy resorufinO-demethylase 
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activity as an index of the catalytic activity of this P-450 isozyme. The kinetic 
inhibition types and K i values were determined by Lineweaver-Burk plots and 
Dixon plots, respectively. Molecular modeling was used to assess the interaction of 
these agents with the CYP1A2 active site. Methoxyresorufin O-demethylase activity 
was inhibited 67 ± 8%, 20 ± 5%, and 7 ± 4% by 2 mm mexiletine, lidocaine, and 
tocainide, respectively. Mexiletine and lidocaine exhibited competitive inhibition 
with K i values of 0.28 ± 0.12 mM and 1.54 ± 0.74 mM, respectively, whereas the 
inhibition type of tocainide could not be determined because of its weak potency. A 
charge interaction between mexiletine and the Asp313 side chain in the CYP1A2 
active site was found, and varying degrees of hydrogen bond formation between 
these three compounds and the CYP1A2 active site were observed. The in vitro 
inhibitory potencies in human liver microsomes (mexiletine>lidocaine>tocainide) 
are consistent with the structural interactions found in a molecular model of the 
active site of CYP1A2. 
YuanfengGao, et al. (2013), studied that Inhibition of Late Sodium Current by 
Mexiletine: A Novel Pharmotherapeutical Approach in Timothy Syndrome is a rare 
LQTS caused by CACNA1Cmutations G406R in exon 8A (TS1) and G402S/G406R 
in exon 8 (TS2). mexiletine, to improve clinical manifestations in TS.Therapeutic 
effects of mexiletine were evaluated using ECG and Holter monitoring. The 
electrophysiologic effect of mexiletine was evaluated in a TS model using rabbit 
ventricular wedges. The proband with severe syndactyly and delayed language skills 
was identified harboring a G406R mutation in CACNA1C. Though asymptomatic he 
exhibited mild QTc prolongation (470-490 ms) and syndactyly. Mexiletine 
shortened QTc from 584 to 515 ms, blunted QT-RR relationship, and abolished 2:1 
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AVB and TWA in the girl. In in-vitro studies, mexiletine inhibited late INa with 
IC50 of 17.6±1.9 µM and attenuated brady-dependent QT prolongation and reduced 
QT-RR slope in the TS model using BayK 8644.  Mexiletine shortened QTc, 
attenuated QT-RR slope, abolished 2:1 AV block and TWA in a TS1 patient and TS 
model via inhibition of late INa.  
Asano K et al., (2003) found out that Attenuating effect of mexiletine hydrochloride 
on herpetic pain in mice infected with herpes simplex virus.The influence of 
mexiletine hydrochloride on herpes-related pain responses was examined using mice 
infected with herpes virus. BALB/c mice were inoculated with herpes simplex virus 
(HSV; 1 × 106 plaque-forming units) on the right hind paw, and the contralateral 
hind paw was without inoculation. The changes in nociceptive threshold were 
examined using electric von fray meter. BALB/c mice inoculated with HSV showed 
a decrease in nociceptive threshold. Intraperitoneal administration of mexiletine 
prevented the decrease in nociceptive threshold dose-dependently in HSV-
inoculated mice, which was firstly observed at a dose of 15.0mg kg-1, and peaked at 
doses more than 17.5 mgkg-1. This antinociceptive effect of mexiletine attained 
peaks at 60-90 min after administration and declined gradually to non-treated levels 
by 150min. mexiletine scarcely affected noradrenaline (norepinephrine) levels in the 
pons and medulla oblongata,even when HSV-inoculated mice were treated with 
17.5mg kg-1 mexiletine. These results strongly suggested that mexiletine exerts 
antinociceptive effects on herpes-related pain through enhancement of β-endorphin 
levels in the central nervous system in HSV-inoculated mice. It is also suggested 
that mexiletine will be a good candidate for an antinociceptive drug in the treatment 
of acute herpetic pain in man. 
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Ging Kuo Wang et al., (2004), studied Mexiletine block of wild-type  and 
inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.  Mexiletine is a 
class 1b antiarrhythmic drug used for ventricular arrhythmias but is also found to be 
effective for paramyotoniacongenita, potassium-aggravated myotonia, long QT–3 
syndrome, and neuropathic pain. This drug elicits tonic block of Na+ channels when 
cells are stimulated infrequently and produces additional use-dependent block during 
repetitive pulses. We examined the state-dependent block by mexiletine in human 
skeletal muscle hNav1.4 wild-type and inactivation-deficient mutant Na+ channels 
(hNav1.4-L443C/A444W) expressed in HEK293t cells with a β1 subunit. The 50% 
inhibitory concentrations (IC50) for the inactivated-state block and the resting-state 
block of wild-type Na+channels by mexiletine were measured as 67.8 ± 7.0 µM and 
431.2 ± 9.4 µM, respectively (n= 5).  
Zeynep aydogmus et al., (2002) developed a new spectrophotometric method based 
on the formation of an ion-pair using bromothymol blue as ion-pair complexing 
reagent for the determination of mexiletine hydrochloride in capsules. The ion-pair 
formed was highly coloured and easily extracted with dichloromethane. The 
calibration curve was linear over the concentration range 1.08{10.8 g.ml −1 at _max 
= 408 nm (r = 0.9999). The results obtained from the developed method were 
compared statistically with those obtained by the British Pharmacopeia method. 
Fukui et al., (2004) Prepared enteric coated timed-release press-coated tablets and 
evaluation of their function by in vitro and in vivo tests for colon targeting As a new 
oral drug delivery system for colon targeting, enteric coated timed-release press-
coated tablets (ETP tablets) were developed by coating enteric polymer on timed-
release press-coated tablets composed of an outer shell of hydroxypropylcellulose 
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and core tablet containing diltiazem hydrochloride (DIL) as a model drug. The 
results of the in vitro dissolution tests in JP 1st fluid (pH 1.2) and JP 2nd fluid (pH 
6.8) indicated that these tablets showed both acid resistance and timed-release. To 
clarify whether ETP tablets could have been of use in the gastrointestinal tract, ETP 
tablets with a layer of phenylpropanolamine hydrochloride (PPA) (a marker of 
gastric emptying) between the enteric coating layer and outer shell were prepared, 
and were administered to beagle dogs. Also, the results seemed to be in accordance 
with the time at which the tablets reached the colon after gastric emptying. 
Therefore, ETP tablets seemed to be an effective tool for oral site-specific delivery 
including targeting of the colon. 
Saita et al, (2003) Development of enzyme-linked immunosorbent assay for 
therapeutic drug monitoring of mexiletine. Anti-mexiletine antibody was obtained 
by immunizing rabbits with an antigen conjugated with mercaptosuccinyl 
bovine serum albumin using N-(epsilon-maleimidocaproyloxy) succinimide as a 
heterobifunctional coupling agent. Enzyme labeling of mexiletine with beta-D-
galactosidase was performed using glutaraldehyde. In this assay, the mexiletine to be 
quantified is chemically modified by acetic anhydride allowed to compete with a 
mexiletine-beta-D-galactosidase conjugate for binding to a limited amount of an 
anti-mexiletine antibody which was used to coat the wells of a microtiter plate. This 
assay was specific for mexiletine and showed very slight cross-reactivity with its 
major metabolite, 2-hydroxymethylmexiletine (1.5%), but none with p-
hydroxymexiletine. The values of serum mexiletine levels from 15 patients by this 
enzyme-linked immunosorbent assay were comparable with those measured by 
HPLC. There was a good correlation between the values determined by the two 
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methods. The enzyme-linked immunosorbent assay should be a valuable tool in 
therapeutic drug monitoring and pharmacokinetic studies of mexiletine. 
Sawada et al., (2003) created a new index, the core erosion ratio, of timed-release 
tablets acetaminophen  and its bioavailability. Although compression-coated tablets 
are a commonly used timed-release drug delivery technology, their utility is often 
limited by poor bioavailability. To try to improve the bioavailability of these tablets, 
the effect of their core composition of compression-coated tablet on in vivo 
pharmacokinetics was investigated. First, the extent of mass reduction of cores in 
different compression-coated tablet core formulations was used to establish a new 
index, the core erosion ratio. The data show that adding excipients with high water 
solubility to the core results in a greater core erosion ratio. Next, to elucidate the 
effect of core erosion ratio on in vivo acetaminophen (AAP) release, three 
compression-coated tablet formulations with similar in vitro AAP release profiles 
but different core erosion ratios were administered to four fasted dogs. These results 
suggest that a formulation with a large core erosion ratio can significantly increase 
in vivo drug release from compression-coated tablets, leading to increased drug 
absorption from the lower GI tract. 
Andrei et al., (2006) The objective of this study was to develop and evaluate a 
pulsatile multiparticulate drug delivery system (DDS), coated with aqueous 
dispersion Aquacoat® ECD. A rupturable pulsatile drug delivery system consists of 
(i) a drug core; (ii) a swelling layer, comprising a superdisintegrant and a binder; and 
(iii) an insoluble, water-permeable polymeric coating. Upon water ingress, the 
swellable layer expands, resulting in the rupturing of outer membrane with 
subsequent rapid drug release.In contrast, a sustained release was achieved after the 
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lag time, when low-substituted hydroxypropyl cellulose (L-HPC) and sodium starch 
glycolate (Explotab®) were used as swelling agents. The optimal level of 
AcDiSol® to achieve a fast and complete release after the lag time was 26% (w/w) 
(based on the weight of the coated pellets). 
Sawada et al., (2004) Time-release compression-coated core tablet containing 
nifedipine  has been formulated and evaluated for chronopharmacotherapy. 
Compression-coated time-release tablets (CC tablets) containing nifedipine, 
dihydropyridine Ca channel blocker, in the core tablet were prepared by dry coating 
with different polyethylene oxide-polyethylene glycol mixtures. Each formulation 
showed a clear lag period before nifedipine release initiation, followed by sustained 
drug release lasting up to 24 h. The lag time of nifedipine release increased as the 
amount of polyethylene oxide in the outer layer increased. To investigate the 
applicability of such CC-tablets for chronopharmacotherapy, the pharmacokinetics 
of CC-1 and CC-2 tablets, with different in vitro lag times before drug release, were 
compared with the pharmacokinetics of a sustained-release (SR) tablet in dogs. 
These results indicate that a CC-tablet with a lag time before drug release is a 
potentially useful formulation for chronopharmacotherapy that can control the time 
and duration of plasma drug concentration better than existing SR technologies. 
Ishibashi et al., (1998) Development of a new capsule-type colon specific 
drug delivery system in healthy volunteers. And its Scintigraphic evaluation. 
Colonic drug delivery is intended for local or systemic therapies. The lack of 
predictive in vitro or animal model leads to considerable time delays in colonic 
product development. The objective of this scintigraphic study was to provide "proof 
of concept" for a novel capsule-type colonic delivery system (Colon-
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Targeted Delivery Capsule) in healthy volunteers. The human data validates 
the design concept behind the release mechanism, in that capsule disintegration, and 
hence drug release, did not start until 5 h after gastric emptying, irrespective of 
whether the product was administered to fasted or fed subjects. However, the 
potential for prolonged gastric residence for large enteric coated products intended 
for intestinal targeting was also observed; overall, the study provides a focus for 
subsequent product development and highlights the role of scintigraphy in 
dynamically visualizing the drug delivery process. 
SharmaS, PawarA (2006) A multiparticulate floating-pulsatile drug elivery system 
was developed using porous calcium silicate (Florite RE) and sodium alginate, for 
time and site specific drug release of meloxicam. Drug adsorbed FLR powder was 
used to prepare calcium alginate beads by ionotropic gelation method, using 3(2) 
factorial design. Entrapment efficiency of different formulations varied from 70% to 
94%. Formulations show a lag period ranging from 1.9 to 7.8 h in acidic medium 
followed by rapid release of meloxicam in simulated intestinal fluid USP, without 
enzymes (SIF). Complete drug release in SIF occurred in less than 1h from the 
formulations. The size of beads varied from 2.0 to 2.7 mm for different batches.  
Floating time was controlled by density of beads and hydrophobic character of drug. 
A pulsatile release of meloxicam was demonstrated by a simple drug delivery 
system which could be useful in chronopharmacotherapy of rheumatoid arthritis. 
Andrea et al.,(2008) evaluated the use of hydrophilic polymers in Oral pulsatile 
delivery systems based on swellable hydrophilic polymers Upon contact with 
aqueous fluids, swellable hydrophilic polymers undergo typical chain relaxation 
phenomena that coincide with a glassy–rubbery transition. In the rubbery phase, 
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these polymers may be subject to swelling, dissolution and erosion processes or, 
alternatively, form an enduring gel barrier when cross-linked networks (hydrogels) 
are dealt with. Because of the peculiar hydration and biocompatibility properties, 
such materials are widely exploited in the pharmaceutical field, particularly as far as 
hydrophilic cellulose derivatives are concerned. In most cases, water-swellable 
polymers play a key role in the overall delivery mechanism after being activated by 
physiological media. Based on these premises, the aim of the present review is to 
survey the main oral pulsatile delivery systems, for which swelling, dissolution 
and/or erosion of hydrophilic polymers are primarily involved in the control of 
release. 
Bruno et al., (1992) given an modelling of mexiletine and hydroxy-methyl-
mexiletine data after single- and multiple-dose administration of a sustained-
release mexiletine formulation. The pharmacokinetics of mexiletine and its 
metabolite hydroxy-methyl-mexiletine have been investigated following single-dose 
and during multiple-dose administration of a sustained-release form of mexiletine to 
six post-myocardial infarct patients. Comparison of single-dose and washout 
pharmacokinetics, after short-term multiple-dose administration, showed significant 
(p < 0.005), The fraction of mexiletine metabolized to hydroxy-methyl-
mexiletine was lower for multiple-dose administration (about 18 per cent) than for 
the single dose (about 42 per cent). The hydroxy-methyl-mexiletine elimination rate 
constant was about four times that of mexiletine. Mexiletine clearance could be 
accounted for by other metabolic pathways. In one patient, hydroxy-methyl-
mexiletine was undetectable even during multiple-dose administration, despite a 
significant increase in mexiletine clearance. However, the observed changes in 
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mexiletine disposition had no therapeutic implications and active plasma levels were 
achieved by the third day of administration and maintained in the therapeutic range 
(0.75 to 2 micrograms ml-1) in all patients after a twice daily dosage regimen. 
Holt et al., (1983) evaluated the Absorption and antiarrhythmic efficacy 
of sustained-release mexiletine. Absorption of the antiarrhythmic agent mexiletine 
from conventional capsules (200 mg) and two sustained-release formulations (360 
and 432 mg) was studied in four healthy volunteer subjects, and use of the 360-mg 
preparation was studied in nine patients who had been using conventional capsules. 
In the four volunteers, acute dosage with the 432-mg preparation produced a 
markedly lower peak mexiletine concentration and fewer side effects than did two 
200-mg capsules. Chronic dosing in two volunteers, which indicated that the 360-
mg preparation produced fewer side effects and lower predose and peak 
plasma mexiletine concentrations than did the 432-mg preparation, suggested the use 
of equivalent doses of the 360-mg preparation in the nine patients who had been 
using 100-, 200-, or 250-mg preparations. The arrhythmia control produced by the 
slow-releasepreparation, as measured by 24-hour ECGs, was comparable to that 
produced by the conventional forms of mexiletine; gastrointestinal side effects were 
less marked when patients took the slow-release preparation, despite higher mean 
predose plasma mexiletine concentrations associated with use of the 360-mg 
preparation. Reduced frequency of daily dosage as well as patient acceptance is 
clinical advantages of the slow-releasepreparation. 
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3. AIM AND PLAN OF WORK 
Aim and Objectives of the study: 
The aim of the present work was formulation and in-vitro evaluation of 
Mexiletine hydrochloride 200mg timed- release capsules. Which release the drug at 
different time intervals in the GI tract 
Objective of the work is to formulate timed release dosage form by adopting 
wet granulation method using synthetic polymers (HPMCE15), Croscormellose 
sodium and Eudragit L 100 at different ratios. 
Mexiletine Hydrochloride was selected as a drug due to its low biological half 
life (A.J.cammn 1990)  it requires frequent administration, hence timed release dosage 
form are formulated to reduce the dosing frequency thereby improving patient 
compliance. 
1. To develop the timed release dosage form of the drug. 
2. To perform drug: excipient compatibility studies. 
3. To determine the drug content of the different granules of various dosage form. 
4. To evaluate parameters such as morphology of the granules, particle size. 
5. To reduce the systemic side effects, and to improve the patient compliance. It is 
delivered through timed-release dosage form. 
6. To conduct the in vitro release studies for the dosage form. 
In case of chronic treatment, where the drug is given in sustained release 
dosage form, continuous exposure of the drug to body may lead to adverse effects. 
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In case of Mexiletine hydrochloride, it is advised to divide the daily dose of 
600-800mg into three does which are given at different time intervals.  This is done to 
reduce the adverse effect as well as it has been reported that clinical outcomes are 
better when three divided doses are given. 
Hence a timed-release dosage form of mexiletine hydrochloride will be 
investigated to deliver the doses at different time intervals in a pulsatile manner.  
Instead of taking three doses at three different time intervals per day, the patient will 
have to take two timed release capsule leading to better patient compliance. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 Aim and Plan of Work 
 
Department of pharmaceutics  40 JKKMMRF college of pharmacy 
 
PLAN OF WORK 
 Preformulation studies: 
• Identification of pure drug: 
• Melting point determination 
• UV Spectroscopy 
• To perform experimental methods 
• To perform analytical methods 
Preparation of timed release drug formulation of Mexiletine hydrochloride by wet 
granulation methods using polymers 
Evaluation of granules 
• Micromeritic properties 
• Angle of repose 
• Bulk density 
• Tapped density 
• Compressibility index 
• Hausner’s ratio 
• Drug content uniformity 
• Drug polymer interaction 
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FTIR to study drug polymer interaction 
In-vitro dissolution studies: 
• Higuchi’s Release model 
• Korsmeyer and Peppas Release model: 
• Zero Order Release Rate Kinetics: 
Accelerated stability study: 
Stability studies for the optimized formulation were carried out at 
40±2˚c/75±5%RH 
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4. MATERIALS AND METHODS 
4.1 Drug profile 
Drug name : Mexiletine hydrochloride 
Structure : 
   
IUPAC name : 2(2-amino propoxy) 1, 3-dimethyl benzene. 
Chemical name  : 1-menthyl-2(2, 6-xylyoxy) ethylamine                    
  Hydrochloride. 
Molecular formula : C11H17NO 
Mol.wt (MW) : 215.73. 
Solubility : Freely Soluble in water and alcohol. 
Category : Anti-arrhythmic agent. 
Storage : 2 to 4oC. 
Melting point : 203-205oC. 
Half life (Hr) : 10-12hrs. 
Indications : For the treatment of ventricular tachycardia and 
  Symptomatic premature ventricular beats and prevention 
  of ventricular fibrillation. Mexiletine hydrochloride is an  
  anti-arrhythmic drug for the treatment of ventricular  
  tachycardia and symptomatic premature ventricular beats,  
  and prevention of ventricular fibrillation. 
  (Drug bank 2005) 
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Clinical pharmacology:  
Mechanism of action: 
Mexiletine structure is similar to local anesthetic drugs  like lignocaine.The 
drug is rapidly absorbed in the GI tract and also has a longer duration of action. It 
inhibits the Inward sodium current required for the initation and conduction of 
impulses, thus reducing the rate of rise of the action potential, phase zero. Mexiletine 
decrease the effective refractory period (ERP) in purkinje fibers in the heart. It is well 
absorbed oral bioavailability from the GI tract. 
Pharmacokinetics:  
Mexiletine is almost completely absorbed orally, 90% metabolized in liver and 
excreted in urine. Plasma is t1/2 9-12 hrs.(Tripati 514) 
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4.2 EXCIPIENTS DATA: 
4.2.1 HYDROXY PROPYL METHYL CELLULOSE (HPMC):
 
Nonproprietary Name 
BP :  Hypromellose 
JP :  Hydroxypropylmethylcellulose 
PhEur :  Hypromellousm 
USP :  Hypromellose 
Synonym   : Benecet MHPC, cellulose, hydroxyl   propyl methyl ether,  
E464; hydroxypropyl methylcellulose; HPMC: Methocel; methylcsllulose propylene  
Glycol ether; methyl hydroxypropylcellulso; Metolose; pharmacist, spectracel 6, 
Spectracel 15, Tylopur.(Hogan 1989) 
Structure 
 
Where R is H, CH3or [CH3CH (OH) CH2] 
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Chemical name : Cellulose, 2-hydroxy propyl methyl ether 
Molecular weight : 10000-150000 
Description : It is an odourless and tasteless, white or creamy white coloured                                                                                 
fibrous power. 
Moisture content : Hypromellose absorbs moisture from the atmosphere; the amount 
of water absorbed depends upon the intial moisture content and the temperature and 
relative humidity of the surrounding air. 
Solubility : It is soluble in cold water; it is practically insoluble in ethanol (95 %) and 
ether. 
Viscosity : Typical viscosity values for 2 % (w/v) aqueous solutions of HPMC 
viscosities measured at 20oc. 
Functional Category 
                 HPMC is serves as a coating agent, film-former, rate-controlling polymer 
for sustained release, stabilizing agent, tablet binder and viscosity-increasing agent. 
Safety 
           Hydroxy propyl methylcellulose is regarded as a nontoxic and nonirritant 
material. 
Stability : It is a stable material, although it is hygroscopic after drying. 
Storage Conditions: It should be stored in a well-closed container, in a cool, dry 
place. 
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Incompatibilities  : HPMC is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts or ionic organics to form 
insoluble precipitates. 
Applications in pharmaceutical technology 
HMPC is widely used in oral and topical pharmaceutical formulations. 
 HPMC is primarily used as a tablet binding in film coating, and as an extended 
 release tablet matrix. 
 HMPC is also used as a suspending and thickening agent for topical 
formulations, particularly ophthalmic preparations. 
 As a protective colloid, it can prevent droplets and particles from coalescing or 
 agglomerating, thus inhibiting the formation of sediments. 
 In addition, HPMC is used in the manufacture of capsules, as an adhesive in 
 plastic bandages, and as a wetting agent for hard contact lenses. 
Table 4.2.1 Viscosity grades and applications: 
Grade Viscosity Application 
E5 5 Film  Coating, Granulating agent 
E15 15 Film Coating, Granulating agent, Suspending 
agent. 
E50 50 Film coating, Granulating agent 
E4M 4000 Sustained release, Medicated gel, Thickening 
agent. 
 
 
Chapter 4 Materials and Methods 
 
Department of pharmaceutics  47 JKKMMRF college of pharmacy 
 
4.2.2 LACTOSE:  
Synonyms Fast-Flo, 4-(β-D-galactosido)-D-glucose, Lactochem, Microtose 
Milksugar Pharmatose, Saccharumlactis, Tablettose, Zeparox.(Raymond et.al,2009) 
Chemical Name : O-β-D-Galactopyranosy1-(1→4)-a-D-glucopyranose  
  monohydrate 
Empirical Formula : C12H22O11H2O  
Molecular Weight : 360.31 
Structural Formula : 
  
Functional Category 
Binding agent, diluents for dry-powder inhalers, tablet binder, tablet and 
capsule diluents. 
Description 
In the solid state, lactose appears as various isomeric forms, depending on the 
crystallization and drying conditions, i.e. ∝-lactose monohydrate and β-lactose 
anhydrous. Lactose occurs as white to off-white crystalline particles or powder. 
Lactose is odorless and slightly sweet-tasting; α-lactose is approximately 20% as 
sweet as sucrose, while β-lactose is 40% as sweet. 
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Safety 
Lactose is widely used in pharmaceutical formulations as a diluents and filler-
binder in Oral capsule and tablet formulations. It may also be used in intravenous 
injections. Adverse reactions to lactose are largely are due to lactose intolerance, 
which occurs in Individuals with a deficiency of the intestinal enzyme lactase, and is 
associated with Oral ingestion of amounts well over those in solid dosage forms. 
Storage Conditions 
Lactose anhydrous should be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities 
A Millard-type condensation reaction is likely to occur between lactose and 
compounds with a primary amine group to form brown, or yellow-brown-colored 
products.  Lactose is also incompatible with amino phenyl-line, amphetamines, and 
lisinop. 
Applications in pharmaceutical technology 
 Lactose is widely used as filler or diluents in tablets and capsules. 
 Lactose is also used as a diluents in dry-powder inhalation. 
 It is also used in lyophilized products, where lactose is added to freeze-dried 
solutions to increase plug size   and aid cohesion. 
 Lactose is also used in combination with sucrose (approximately 1:3) to 
prepare sugar-coating solutions. 
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4.2.3. CROSCARMELLOSE SODIUM (CCS): 
Non proprietary names 
BP                                : Croscarmellose Sodium 
JP                                 : Croscarmellose Sodium 
PhEur                           : Croscarmellose Sodium 
USP-NF                       : Croscarmellose Sodium 
Synonyms: Carmellosumnatricumconexum; crosslinkedcarboxymethyl cellulose 
Sodium; Explocel; modified cellulose gum.(Raymond et.al,2009) 
Structure                                    
 
Chemical name : Cellulose, carboxymethyl ether. 
Functional Category : Tablet and capsule disintegrant 
Description : Croscarmellose sodium occurs as an odorless, white or  
  grayishwhite powder. 
Solubility      : Insoluble in water.  Practically insoluble in acetone, ethanol  
  and toluene. 
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Stability        : Croscarmellose sodium is stable though hygroscopic  
  material. 
Storage        : The bulk material should be stored in a well-closed container  
  in a cool, dry place. 
Applications in pharmaceutical technology 
  In tablet formulations, croscarmellose sodium may be used in both direct-
compression and wet-granulation processes.  
When used in wet granulations, the croscarmellose sodium should be added in 
both the wet and dry stages of the process (intra- and extragranulary) so that the 
wicking and swelling ability of the disintegrant is best utilized. 
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4.2.4 MAGNESIUM STERATE: 
Nonproprietary Names 
BP                                  :   Magnesium Stearate 
JP                                   :   Magnesium Stearate 
PhEur                             :   Magnesium Stearate 
USP-NF                         :   Magnesium Stearate 
Synonyms 
               Dibasic magnesiumstearate, magnesium distearate, magnesistearas, 
magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid.( 
Raymond et.al,2009). 
Chemical Name           :  Octadecanoic acid magnesium salt. 
Structural formula      :  [CH3 (CH2)16COO] 2Mg 
Functional Category   :  Tablet and capsule lubricant 
Description: Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste.  The powder is greasy to the touch and readily adheres to the skin. 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol. 
Stability & Storage Conditions 
Magnesium stearate is stable and should be stored in a well-closed container in 
a cool, dry place. 
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Applications in pharmaceutical technology 
It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. Magnesium stearate is widely used in 
cosmetics, foods, and pharmaceutical   formulations. It is also used in barrier creams. 
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4.2.5 EUDRAGIT: 
Nonproprietary names 
BP                         :    Methacrylic Acid-Methyl Methacrylate Copolymer 
PhEur                    :    Methacrylic Acid-Methyl Methacrylate Copolymer 
USP-NF                :    Methacrylic Acid-Methyl Methacrylate Copolymer 
Synonyms  
Acryl-EZE; acidimethacrylici et ethylisacrylatispolymerisatum; acidimethacrylici 
et methylismethacrylatispolymerisatum; ammoniomethacrylatiscopolymerum; 
copolymerummethacrylatisbutylatibasicum; Eastacsryl; Eudragit; Kollicoat MAE; 
polymeric methacrylates.(Raymond et.al,2009) 
Structure  
For Eudragit L: R1, R3 = CH3, R2 = H, R4 = CH3. 
Chemical name : Poly (methacrylic acid, methyl methacrylate) 
Functional Category : Film-forming agent; tablet binder; tablet diluents. 
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Description: Eudragit L and S, also referred to as methacrylic acid copolymers in the 
USP32-NF27 monograph, are anionic copolymerization products of methacrylic acid 
and methyl methacrylate.  That ratio of free carboxyl groups to the ester is 
approximately 1 :1 in Eudragit L (Type A) and approximately 1 : 2 in Eudragit S 
(Type B).  Both polymers are readily soluble in neutral to weakly alkaline Conditions 
(pH 6-7). 
Solubility: Eudragit L 100 is an enteric coated polymer. It is soluble in acetone, 
alcohols and intestinal fluid. 
Stability: Dry powers are stable for at least 3 years if stored in a tightly closed 
container at less than 30°C. 
Incompatibilities 
Depending upon the ionic and physical properties of the polymer and solvent.  
For example, coagulation may be soluble electrolytes, pH changes, some organic 
solvents, and extremes of temperature.  For example, dispersions of Eudragit L 30D, 
RL 30, L 100-55, and RS 30 D are incompatible with magnesium stearate. 
Applications in pharmaceutical technology: Polymethacrylates are primarily used 
in oral capsule and tablet formulations as film-coating agents.  Depending on the type 
of polymer used; Eudragit L is soluble at pH>6.  Polymethacrylates are also used as 
binders in both aqueous and organic wet-granulation processes. 
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4.2.6 TALC:   
Nonproprietary names 
BP                       :    Purified Talc 
JP                        :    Talc 
PhEur                  :    Talc 
USP                     :    Talc 
Synonyms: Hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Imperial; Luzenac Pharma; magnesium hydrogen metasilicate; MagsilOsmanthus; 
Magsil Star; powdered talc; purified French chalk; Pure French talc; soapstone; 
steatite; Superiore; talcum. (Raymond et.al,2009) 
Functional Category: Ant caking agent; glidant; tablet and capsule diluents; tablet 
and capsule lubricant. 
Description: Talc is a very fine, white to grayish-white, odorless, impalpable, 
crystalline powder.  It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Solubility: Practically insoluble in dilute acids and alkalis, organic solvents, and 
water. 
Stability and Storage Conditions:  Talc is a stable material and may be sterilized by 
heating at 160°C for not less than 1 hour.  It may also be sterilized by exposure to 
ethylene oxide or gamma irradiation.  Talc should be stored in a well-closed container 
in a cool, dry place. 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
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Applications in pharmaceutical technology: Talc was once widely used in oral 
solid dosage formulations as a lubricant and diluents, although today it is less 
commonly used.  However, it is widely used as a dissolution retardant in the 
development of controlled-release products. 
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4.2.7 POLYVINYL PYRROLIDINE: 
Nonproprietary names 
BP                     :        Polyvinyl pyrrolidine 
USP                   :        Polyvinyl pyrrolidine 
Structure 
 
Chemical name 
Poly (1-(2-oxo-1-pyrrolidinyl)ethylen) 1-ethenyl-2-pyrrolidon homopolymer 1-vinyl-
2-pyrrolinon-polymer copovidone.(Heburtus and Ansul 2008) 
Empirical formula : (C6H9NO)n 
Molecular weight : 44,000-54,000 
Functional category : Binding agent 
Solubility : Soluble in water and hydrophilic, hydrophobic solvents 
Description : White to yellow-white powder 
Storage : It should be stored in air tight Containers. 
Applications is pharmaceutical technology : 
Numerous applications in medicine, cosmetics. 
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4.3 Materials used: 
Table 4.3.1-List of materials used: 
Sl. No. Excipients Vendor 
1. Maxiletine hydrochloride Sigma Aldrich, China 
2. Lactose SD fine chemicals, Mumbai 
3. Cross carmellose sodium Waksman SlemanPvt Ltd, Atp 
4. Poly vinyl pyrrolidine Waksman SlemanPvt Ltd, Atp 
5. HPMC E15 Waksman SlemanPvt Ltd, Atp 
6. Eudragit L 100 Waksman SlemanPvt Ltd, Atp 
7. Magnesium stearate Lobachemie, Mumbai 
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Equipments used 
Table 4.3.2: List of equipments used in the present work is as follows: 
S.NO Instruments Source 
1. Digital Electronic balance AX200 Shimadzu corporation, Japan 
2. Digital pH meter Digisum electronics system, 
Hyderapad. 
3. UV/Visible spectrophotometer, 1700 Shimadzu corporation, Japan 
4. Digital Weighing Balance Ohaus, SP:202, USA 
5. Dissolution apparatus Labindia, Mumbai. 
6. Hot air oven Labline, Cochian 
7. FTIR spectrophotometer Shimadzu Corporation, Japan 
8. DSC SDT Q600 V8.2 build 100 
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4.4. METHODOLOGY: 
4.4.1.PREFORMULATION STUDIES: 
Preformulation is the first step in the rationale development of dosage forms of 
a drug substance.  It can be defined as an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients.  The overall 
objective of preformulation testing is to generate information useful to formulator in 
developing stable and bioavailable dosage forms which can be mass-produced. 
4.4.1.1. Identification of pure drug: Identification of Mexiletine HC1 was carried 
out by Infrared Absorption Spectrophotometry. 
4.4.1.2. Melting point determination: Melting point of Mexiletine HC1 was 
determined by Open capillary method. 
4.4.1.3 UV Spectroscopy: 
The first step in preformulation is to establish a simple analytical method so 
that all future measurements can be quantitative.  Most drugs absorb light in the 
ultraviolet wavelengths (200-400nm), since they are generally aromatic or contain 
double bonds.  
 Preparation of the sample for UV analysis  
10mg of Mexiletine HC1 was accurately weighed on a microbalance and 
dissolved in 10ml water (=1000mcg/ml).  Water is UV transparent and a good solvent 
for most polar and non-polar drugs.  1ml of this solution was diluted with 100ml of 
pH 1.2, pH6.8 and pH7.4 (=10mcg/ml) in separate volumetric flask and scanned on a 
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UV scanner between 200 to 400nm.  The maxima obtained in the graph were 
considered as λmax for the pure drug at respective buffers. 
4.5 Calibration curves 
Experimental methods 
Sodium hydroxide solution, 0.2M: Eight grams of sodium hydroxide was dissolved 
in distilled water and diluted to 1000 ml with distilled water. 
Potassium dihydrogen phosphate solution, 0.2 M: Potassium dihydrogen phosphate 
(27.218 g) was dissolved in distilled water and diluted to 1000 ml. 
Hydrochloric acid solution, 0.1 N: Concentrated hydrochloric (8.5 ml) acid was 
diluted with distilled water and volume was made up to 1000 ml with distilled water.  
pH (1.2) was adjusted with dilute hydrochloric acid. 
Phosphate buffer solution, pH 6.8: Potassium dihydrogen phosphate, 250 ml of 0.2 
M, was placed in a 1000 ml volumetric flask, 112 ml of 0.2 M sodium hydroxide was 
added and then volume was adjusted with distilled water up to 1000 ml.  pH was 
adjusted to 6.8 with dilute sodium hydroxide. 
Phosphate buffer solution, pH 7.4: Potassium dihydrogenphosphate, 250 ml of 
0.2M, was placed in a 1000 ml volumetric flask, 195.5 ml of 0.2M sodium hydroxide 
was added and then volume was adjusted with distilled water up to 1000 ml.  pH was 
adjusted to 7.4 with dilute sodium hydroxide. 
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Analytical Methods 
4.5.1 Preparation of calibration curve in water: 
 An accurately weighted amount of Mexiletine HC1 equivalent to 100 mg was 
dissolved in small volume of water, in 100 ml volumetric flask and the volume 
was adjusted to 100 ml with water (stock I).  Form stock I 5ml of solution is 
transferred to 50 ml volumetric flask (stock II).  A series of standard solution 
containing Beer-Lambert’s range of concentration from 5 to 2 µg/ml of 
Mexiletine HC1 were prepared from stock II and absorbance was measured at 
262 nm spectrophotometrically against water buffer as blank. 
4.5.2 Preparation of calibration curve in 1.2pH buffer: 
 An accurately weighted amount of Mexiletine HC1 equivalent to 100 mg was 
dissolved in small volume of 1.2 buffer, in 100 ml volumetric flask and the 
volume was adjusted to 100 ml with 1.2 pH buffer (stock I).  From stock I 5ml 
of solution is transferred to 50ml volumetric flask (stock II).  A series of 
standard solution containing Beer-Lambert’s range of concentration from 5 to 
25µg/ml of Mexiletine HC1 were prepared from stock II and absorbance was 
measured at 262 nm spectrophotometrically against 1.2 pH buffer as blank. 
4.5.3 Preparation of calibration curve in 7.4 pH buffer: 
 An accurately weighed amount of Mexiletine HC1 equivalent to 100 mg was 
dissolved in small volume of buffer, in 100 ml volumetric flask and the 
volume was adjusted to 100 ml with 7.4 pH buffer (stock I).  From stock I 5ml 
of solution is transferred to 50 ml volumetric flask (stock II).  A series of 
standard solution containing Beer-Lambert’s range of concentration from 5 to 
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25µg/ml of Mexiletine HC1 were prepared from stock II and absorbance was 
measured at 262 nm spectrophotometrically against 7.4 pH buffer as blank. 
4.5.4 Preparation of calibration curve in 6.8 pH buffer: 
 An accurately weighed amount of Mexiletine HC1 equivalent to 100 mg was 
dissolved in small volume of buffer, in 100 ml volumetric flask and the 
volume was adjusted to 100 ml with 6.8 pH buffer (stock I).  From stock I 5ml 
of solution is transferred to 50 ml volumetric flask (stock II).  A series of 
standard solution containing Beer-Lambert’s range of concentration from 5 to 
25µg/ml of Maxiletine HC1 were prepared from stock II and absorbance was 
measured at 262 nm spectrophotometrically against 6.8 pH buffer as blank, 
4.6 Formulation development 
Granules preparation: 
Granules preparation is done by wet granulation method. 
 All the ingredients including drug and polymer, and excipients are weighed 
accurately according to formula mentioned in table 4.3 to 4.8 
• All the ingredients are passed through a 24mesh sieve. 
• Required quantity of drug, diluents and polymers are mixed thoroughly 
sufficient qty of binding agent polyvinyl pyrrolidine added slowly. 
• After enough cohesiveness mass was obtained, the mass was sieve through a 
16mesh sieve. 
• The granules were dried at 50˚c for 45 minutes and were blended with 
magnesium stearate and talc 
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Table 4.3 Formulation of F1: 
Formulation 
ingredients 
Granule 
composition-1 
Granule 
composition-2 
Granule 
composition-3 
(pH1.2granules) (pH 6.8granules) (pH 7.4granules) 
Mexiltine HC1 200mg 200mg 200mg 
Lactose 40mg - - 
Croscarmellose 
sodium 
8mg - - 
HPMC E15 - 20mg - 
Eudragit L 100 - - 40mg 
PVP K 1% 1% 1% 
Magnesium stearate 5mg 5mg 5mg 
Talc 5mg 5mg 5mg 
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Table 4.4 Formulation of F2: 
Formulation 
ingredients 
Granule 
composition-1 
Granule 
composition-2 
Granule 
composition-3 
(pH1.2granules) (pH 6.8granules) (pH 7.4granules) 
Mexiltine HC1 200mg 200mg 200mg 
Lactose 40mg - - 
Croscarmellose 
sodium 
8mg - - 
HPMC E15 - 25mg - 
Eudragit L 100 - - 60mg 
PVP K 1% 1% 1% 
Magnesium stearate 5mg 5mg 5mg 
Talc 5mg 5mg 5mg 
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Table 4.5 Formulation of F3: 
Formulation 
ingredients 
Granule 
composition-1 
Granule 
composition-2 
Granule 
composition-3 
(pH1.2granules) (pH 6.8granules) (pH 7.4granules) 
Mexiltine HC1 200mg 200mg 200mg 
Lactose 40mg - - 
Croscarmellose 
sodium 
8mg - - 
HPMC E15 - 30mg - 
Eudragit L 100 - - 60mg 
PVP K 1% 1% 1% 
Magnesium stearate 5mg 5mg 5mg 
Talc 5mg 5mg 5mg 
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Table 4.6 Formulation of F4: 
Formulation 
ingredients 
Granule 
composition-1 
Granule 
composition-2 
Granule 
composition-3 
(pH1.2granules) (pH 6.8granules) (pH 7.4granules) 
Mexiltine HC1 200mg 200mg 200mg 
Lactose 40mg - - 
Croscarmellosesodium 8mg - - 
HPMC E15 - 40mg - 
Eudragit L 100 - - 60mg 
PVP K 1% 1% 1% 
Magnesium stearate 5mg 5mg 5mg 
Talc 5mg 5mg 5mg 
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Table 4.7 Formulation of F5: 
Formulation 
ingredients 
Granule 
composition-1 
Granule 
composition-2 
Granule 
composition-3 
(pH1.2granules) (pH 6.8granules) (pH 7.4granules) 
Mexiltine HC1 200mg 200mg 200mg 
Lactose 40mg - - 
Croscarmellose 
sodium 
8mg - - 
HPMC E15 - 60mg - 
Eudragit L 100 - - 80mg 
PVP K 1% 1% 1% 
Magnesium stearate 5mg 5mg 5mg 
Talc 5mg 5mg 5mg 
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Table 4.8 Formulation of F6: 
Formulation 
ingredients 
Granule 
composition-1 
Granule 
composition-2 
Granule 
composition-3 
(pH1.2granules) (pH 6.8granules) (pH 7.4granules) 
Mexiltine HC1 200mg 200mg 200mg 
Lactose 40mg - - 
Croscarmellose 
sodium 
8mg - - 
HPMC E15 - 80mg - 
Eudragit L 100 - - 1 00mg 
PVP K 1% 1% 1% 
Magnesium stearate 5mg 5mg 5mg 
Talc 5mg 5mg 5mg 
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4.7 Evaluation of granules: 
Prepared granules were evaluated for the following parameters(Ishikawa 
et.al,2000,Raghuram et.al,2003,Banker et.al,2001) 
4.7.1 Angle of repose:  
The angle of repose of the powder blend was determined by using funnel 
method. The accurately weighed powder was taken in a funnel. The height of the 
funnel was adjusted in such a way that the tip of the funnel just touched the apex of 
the heap of the powder.  The diameter of the cone was measured and angle of repose 
was calculated by using the equation, 
  θ=tan-1h/r 
where, 
                    h = height of the cone 
r = radius of the cone 
 Flow properties for different values of angle of repose were given below. 
Table-4.9 Flow property of powders according to angle of repose: 
 
 
 
 
 
Angle of Repose (θ 
degrees) 
Flow property 
<25 Excellent 
25 - 30 Good 
30 - 40 Passable 
>40 poor 
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4.7.2 Bulk density: 
An amount of powder blend was introduced in a 100 ml measuring cylinder.  
Then the weight of powder blend was determined by subtracting the weight of empty 
measuring cylinder from final weight of measuring cylinder.  The cylinder was 
allowed to fall onto a hard surface from a height of 2.5 cm at 2 sec intervals.  The 
tapping was continued till no volume change noted.  Bulk density was calculated by 
using the formula; 
                                                                   Mass(gm) 
   Bulk density =------------------------ 
     Volume(ml) 
4.7.3 Tapped density: 
Now this cylinder was put in the holder of USP tapped density apparatus 
where it was tapped at an average rate of 300 drops / minute, for 500 taps.  After 500 
taps volume of powder (V0) was noted and again tapped for another 750 taps.  This 
gave a new volume (Vf). If the difference between v0 and vf was more than 2% 
another 1250 taps are given repeatedly until the difference reduces to less than 
2%.Tapped density was found out from following equation: 
                                                           Mass(gm)          .          
Tapped density = ----------------------------- 
     Tapped volume(ml) 
4.7.4 Compressibility index: The compressibility of the powder was determined by 
the Carr’s compressibility index. 
                                     Tapped bulk destiny – Loose bulk density  
Carr’s index=      ----------------------------------------------------------------- X 100 
               Tapped volume (ml) 
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Table-4.10 Grating of powders according to Carr’s index; 
Compressibility index Flow property 
5-15 Excellent 
12-16 Good 
18-21 Fair to Passable 
23-35 Poor 
33-38 Very poor 
 
4.7.6 Hausner’s ratio: 
Hausner’s ratio is an indirect index of ease of measuring the powder flow.  It 
is calculated by the following formula: 
 Hausner’s ratio =   Tapped density/ Bulk density 
4.7.7 Drug content uniformity: 
In 100 ml volumetric flask 750mg equivalent weight of granules are taken and 
dissolved in small quantity of water and the volume was made up to mark with pH 7.4 
buffer and stirred for 12 hrs.  After stirring the solution was filtered through whatman 
filter paper and from the filtrate dilutions were made and absorbance was measured 
spectrophotometrically at 262nm. 
4.7.8 Drug polymer interaction: 
FT-IR spectra of physical mixture of Mexiletine HC1+Lactose, Mexiletine 
HC1+Croscarmellose sodium, Mexiletine HC1+PVPk, Mexiletine HC1+Hpmc E15, 
mexilitine HC1+Eudragit L 100, Mexiletine HC1+Mg.Sterate were determined by 
using KBr pellet technique.  Samples were scanned over the 4000-400cm-1.  Spectral 
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region at resolution of 4cm-1.  These studies are done to ensure no interaction has been 
occurred between the drug and polymer. 
4.8 Data analysis: 
To analyse the mechanism of the drug release rate kinetics of the dosage form, the 
data obtained were graphed as 
1) Cumulative percentage drug released v/s time(In-vitro drug release profile) 
2) Cumulative percentage drug released v/s Square root of time (Higuchi’s plots) 
3) Log cumulative percentage drug remaining v/s time (First order release) 
4) Log percentage drug released v/s log time (Peppas plots)(Nish demn 2003) 
4.8.1 In-vitro release profile: 
Dissolution studies were carried out by using USP Type-1 dissolution test 
apparatus (Basket) method.  In order to simulate the pH changes along the GI tract, 
three dissolution media with pH 1.2, 7.4 and 6.8 were sequentially used referred to as 
sequential pH change method.  When performing experiments, the pH 1.2 medium 
was first used for 2 hrs (since the average gastric emptying time is 2 hrs) then 
removed and the fresh pH 7.4 phosphate buffer saline (PBS) was added.  After 6 hrs 
(average small intestinal transit time is 6 hrs) the medium was removed and fresh pH 
6.8 dissolution medium was added for subsequent hrs.  900ml of the dissolution 
medium was used at each time.  Rotation speed was 100 rpm and temperature was 
maintained at 37±0.5˚C five milliliters of dissolution media was withdrawn at 
predetermined time intervals and fresh dissolution media was replaced.  The 
withdrawn samples were analyzed at 262 nm, by UV absorption spectroscopy. 
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4.8.2 Higuchi’s Release model: 
To study the Higuchi release kinetics, the release rate data were fitted to the 
following equation, 
F = K.t1/2 
Where, ‘F’ is the amount of drug release, 
 ‘K’ is the release rate constant, and 
 ‘t’ is the release time. 
When the data is plotted as accumulative drug released versus square root of 
time, yields a straight line, indicating that the drug was released by diffusion 
mechanism.  The slope is equal to ‘K’. 
4.8.3 Korsmeyer and Peppas Release model: 
The release rate data were fitted to the following equation, 
Mt/M∞ = K.tn 
Where, Mt /M∞ is the fraction of drug release,  
           ‘K’ is the release constant,  
           ‘t’ is the release time,  
           ‘n’ is the diffusional exponent for the drug release that is dependent on the 
shape of the matrix dosage form. 
When the data is plotted as Log of drug released versus Log time, yields a 
straight line with a slope equal to ‘n’ and the ‘K’ can be obtained from Y – intercept. 
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4.8.4 Zero Order Release Rate Kinetics: 
To study the zero-order release kinetics the release rate date are fitted to the 
following equation. 
F = K.t 
Where ‘F’ is the fraction of drug release, ‘K’ is the release rate constant and ‘t’ 
is the release time. 
When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys zero-order release kinetics, with a slope equal to K0. 
4.9 Accelerated stability studies: 
Stability studies for the optimized formulation were carried out at 
40±2˚c/75±5% RH for 6weeks.  Stability studies were carried out using Thermo lab 
stability chamber.  After 4weeks the optimized formulation was tested for physical 
appearance, drug content and DSC.  
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5. RESULTS AND DISCUSSION 
5.1 PREFORMULATION STUDIES 
5.1.1. Infrared spectroscopy: 
The drug is identified as an mexiletine hydrochloride by the observation of 
peaks in the following region cm-1 2590, 1616, 850, 1487, 1616 which is compared to 
the standard. 
5.1.2 Melting point determination: 
Melting point of Mexiletine HC1 was determined by Open capillary method. 
The results are tabulated in the table 5.1 
Table 5.1 Melting point determination of Mexiletine hydrochloride 
Trail1 Trail2 Trail3 Average 
199°c 201°c 202°c 201°c 
    
By comparing to the standard melting point which is found to be 203-2050c 
(drug bank DBOO379) it is more or less equal to the standard. 
5.1.2 UV Spectroscopy:   
UV scanning of the drug revealed that the drug had max of 262 nm in 
distilled water. Also, the IR spectrum was concordant with the reference spectrum of 
Mexiletine  hydrochloride.   
 
 
 
Chapter 5 Results and Discussion 
 
Department of pharmaceutics  77 JKKMMRF college of pharmacy 
 
 
 
 
 
 
 
 
 
Fig 5.1 Wavelength scans of pure drug 
5.2 Calibration curves 
Calibration curve has been drawn using different solutions like water and 
buffers 1.2, 6.8, 7.4.and the graphs are under the following tables 5.2 to 5.5. 
  
Chapter 5 Results and Discussion 
 
Department of pharmaceutics  78 JKKMMRF college of pharmacy 
 
 
Table 5.2 Calibration data of Mexiletine hydrochloride in water: 
Concentration 
(µg/ml) 
Trail1 Trail2 Trail3 Absorbance 
±SD* 
0 0 0 0 0 
5 0.061 0.060 0.078 0.066±0.010 
10 0.118 0.117 0.128 0.122±0.005 
15 0.171 0.178 0.181 0.176±0.005 
20 0.206 0.240 0.246 0.230±0.021 
25 0.280 0.300 0.298 0.292±0.007 
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Table5.3 Calibration data of Mexiletine HC1 in 1.2 buffer 
Concentration 
(µg/ml) 
Trail1 Trail2 Trail3 Absorbance 
±SD* 
0 0 0 0 0 
5 0.071 0.078 0.070 0.073±0.004 
10 0.132 0.128 0.130 0.130±0.002 
15 0.181 0.181 0.175 0.179±0.003 
20 0.244 0.246 0.230 0.240±0.008 
25 0.308 0.298 0.290 0.298±0.009 
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Table5.4 Calibration data of Mexiletine  HC1 in 7.4 buffer 
Concentration 
(µg/ml) 
Trail1 Trail2 Trail3 Absorbance 
±SD* 
0 0 0 0 0 
5 0.081 0.079 0.073 0.077±0.004 
10 0.157 0.158 0.140 0.151±0.010 
15 0.225 0.221 0.205 0.271±0.010 
20 0.307 0.305 0.280 0.297±0.015 
25 0.380 0.370 0.360 0.370±0.01 
 
 
Fig 5.4 Calibration Curve of Mexiletine HCI in 7.4 buffer 
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Table 5.5 Calibration data of Mexiletine HC1 in 6.8 buffer 
Concentration 
(µg/ml) 
Trail1 Trail2 Trail3 Absorbance 
±SD* 
0 0 0 0 0 
5 0.045 0.059 0.040 0.049±0.009 
10 0.147 0.160 0.150 0.152±0.006 
15 0.215 0.220 0.205 0.213±0.007 
20 0.297 0.312 0.295 0.310±0.009 
25 0.370 0.360 0.340 0.323±0.015 
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Discussion 
From the standard curve of mexiletine hydrochloride,it was observed that the 
drug obeys Beer- Lambert’s law in concentration range of 5-25µg/ml in water. The 
linear regression equation generated was used for the calculation of amount of drug. 
5.3 Drug and polymer compatibility 
Infrared analysis has been carried out to check the polymer compatibility with the 
polymers and the graph has been given in the following figures 5.6 to 5.12
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                                          Fig 5.7 IR spectrum of Drug and Lactose 
 
 
 
Fig 5.8 IR spectrum of Drug and Croscarmellose Sodium 
Chapter 5 Results and Discussion 
 
Department of pharmaceutics  84 JKKMMRF college of pharmacy 
 
 
                                         Fig 5.9. IR spectrum of Drug and HPMC 
 
 
 
Fig 5.10 IR spectrum of Drug and PVP-K 
Chapter 5 Results and Discussion 
 
Department of pharmaceutics  85 JKKMMRF college of pharmacy 
 
 
Fig 5.11 IR spectrum of Drug and Eudragit L 100 
 
 
Fig 5.12 IR spectrum of Drug and magnesium stearate 
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Discussion: 
Physical mixture of drug and polymer was characterized by FT-IR & DSC spectral 
analysis for any physical as chemical alteration of the drug characteristics. From the 
result it was concluded that there was no interference of the functional groups as the 
principal peaks of the mexiletine hydrochloride were found to be unaltered in the 
spectra of the drug-polymer physical mixture. And its wave number has been given in 
the following table. 
Table 5.6 INTERPRATION DATA OF IR ANALYSIS: 
Wave 
number 
Functional 
group 
Peaks 
observed in 
cm-1 
Drug Polymers Interaction 
2450-2700 C-N 2590 YES YES NO 
1250-1750 C=O 1616 YES YES NO 
900-675 C-H 850 YES YES NO 
1500-1400 C-C 1487 YES YES NO 
1600-1700 N-H 1616 YES YES NO 
 
5.4 Evaluation of granules 
Six formulations of matrix granules were prepared (F1 to F6) by using various 
polymers such as HPMC E15 and Eudragit L100 in different ratios. The granules 
were prepared by wet granulation method. 
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Table 5.7 Evaluation parameters of Mexiletine HC1 matrix granules 
 
Discussion: 
 Pre compression evaluation 
Carr’s compressibility index was found to be less than 20% for all the formulations 
indicating that the powder is compressible. Bulk density and true densities were found 
to be <1 for all formulation powders. The result of Angle repose studies and Hausner,s 
ratio indicated that, the powders of all the formulations have free flow and easily 
compressible. 
  
Formulation Angle of 
repose(degree) 
Bulk 
density 
Tapped 
density 
Compressibility 
index 
Hausner’s 
ratio 
F1 27.23° 0.596 0.748 18.45 1.289 
F2 28.36° 0.623 0.736 17.95 1.245 
F3 26.46° 0.601 0.740 18.98 1.356 
F4 28.76° 0.612 0.750 18.36 1.225 
F5 29.21° 0.589 0.725 18.65 1.198 
F6 29.56° 0.623 0.745 18.24 1.244 
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5.4.1 Drug content uniformity:  
In these all the formulations the percentage of drug release has been 
mentioned in the table 5.7 
Table 5.8  Drug content uniformity of matrix granules 
Formulation % Cumulative drug 
release 
F1 86.6% 
F2 88.0% 
F3 87.3% 
F4 93.3% 
F5 85.3% 
F6 84.0% 
 
The drug content uniformity was found to be 93.3 w/w%. 
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5.5 Post Compression evalution: 
5.5.1 invitro release profile: 
Table 5.9 Dissolution profile of formulation of F1 
Time absorbance C in 
mcg 
C in V 
Made up 
C in 
D.M Loss CLA CDR %CDR 
C%D 
Retained 
Log 
%CD 
released 
Log %CD 
Retained 
5 0.063 5.72727 0.057273 51.545 0 0 51.54545 25.77273 74.227 1.41116 1.8705635 
10 0.089 8.09091 0.080909 72.818 0.0573 0.057273 72.87545 36.43773 63.562 1.561551 1.8031994 
20 0.095 8.63636 0.086364 77.727 0.0809 0.138182 77.86545 38.93273 61.067 1.590315 1.7858085 
30 0.11 10 0.1 90 0.0864 0.224545 90.22455 45.11227 54.888 1.654295 1.7394752 
40 0.114 10.3636 0.103636 93.182 0.1 0.324545 93.59727 46.79864 53.201 1.670233 1.7259228 
50 0.12 10.9091 0.109091 98.182 0.1036 0.428182 98.61 49.305 50.695 1.692891 1.7049651 
60 0.128 11.6364 0.116364 104.73 0.1091 0.537273 105.2645 52.63227 47.368 1.721252 1.6754825 
120 0.132 12 0.12 108 0.1164 0.653636 108.6536 54.32682 45.673 1.735014 1.6596613 
180 0.022 1.46667 0.014667 13.2 0 0 13.2 6.6 93.4 0.819544 1.9703469 
240 0.024 1.6 0.016 14.4 0.0147 0.014667 14.41467 7.207333 92.793 0.857775 1.9675137 
300 0.013 0.86667 0.008667 7.8 0.016 0.030667 7.830667 3.915333 96.085 0.592769 1.9826541 
360 0.014 0.93333 0.009333 8.4 0.0087 0.039333 8.439333 4.219667 95.78 0.625278 1.9812763 
420 0.02 1.33333 0.013333 12 0.0093 0.048667 12.04867 6.024333 93.976 0.779909 1.9730154 
480 0.022 1.46667 0.014667 13.2 0.0133 0.062 13.262 6.024333 93.369 0.821579 1.9702027 
540 0.002 2 0.02 18 0 0 18 9 91 0.954243 1.9590414 
600 0.016 1 0.01 9 0.02 0.02 9.02 4.51 95.49 0.654177 1.9799579 
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Table 5.10 Dissolution profiles of formulation of F2 
 
Time Absorbance Cin mcg Cin V 
made up Cin D.M Loss CLA CDR %CDR 
C% D 
Retained 
Log% 
CD 
Released 
Log % 
CD 
Retained 
5 0.056 5.09091 0.050909 45.81818 0 0 45.81818 22.90909 77.0909 1.36008 1.8870032 
10 0.064 5.8181 0.058182 52.36364 0.050909 0.050909 52.41455 26.20727 73.7927 1.418422 1.8680136 
20 10.088 8 0.08 72 0.05818 0.109091 72.10909 36.05455 63.9455 1.55696 1.8058097 
30 0.11 10 0.1 90 0.08 0.18991 90.18909 45.09455 54.9055 1.654124 1.76396155 
40 0.121 11 0.11 99 0.1 0.289091 99.28909 49.64455 50.3555 1.695872 1.7020465 
50 0.13 11.8182 0.118182 106.3636 0.11 0.3990914 106.7627 53.38136 46.6186 1.72739 1.6685596 
60 0.136 12.3636 0.1253636 111.2727 0.118182 0.517273 111.79 55.895 44.105 1.747373 1.6444878 
120 0.1478 12.8182 0.128182 115.3636 0.123636 0.640909 116.0045 58.00227 41.9977 1.763445 1.6233258 
180 0.09 6 0.06 54 0 0 54 27 73 1.43136 1.86332 
240 0.085 5.66667 0.056667 51 0.06 0.06 51.06 25.53 74.47 1.407051 1.8719814 
300 0.08 5.33333 0.053333 48 0.056667 0.116667 48.11667 24.05833 75.9417 1.396303 1.8820405 
360 0.079 5.26667 0.052667 47.4 0.053333 0.17 47.57 23.785 76.215 1.376303 1.88204058 
420 0.06 4 0.04 36 0.052667 0.222667 36.22267 18.11133 81.8887 1.25795 1.9132238 
480 0.058 3.86667 0.038667 34.8 0.04 0.262667 35.06267 17.563133 82.4687 14.243815 1.916289 
600 0.007 7 0.07 63 0.09 0.09 63.09 31.545 68.454 1.498931 1.8628467 
660 0.006 6 0.06 54 0.07 0.16 54.16 27.08 72.92 10432649 1.8628467 
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Table 5.11 Dissolution profiles of formulation of F3 
 
Time Absorbance CONC (mcg) 
C in V 
made up 
C in 
disso 
medium 
Loss CLA CDR %CDR C%D Retained 
Log% CD 
Released 
Log %CD 
Retained 
5 0.054 4.909091 0.04909091 44.18182 0 0 44.18182 22.09091 77.909 1.3442136 1.8915881 
10 0.062 5.636364 0.05636364 50.72727 0.049091 0.049091 50.77636 25.38818 74.612 1.0406316 1.8728076 
20 0.082 7.454545 0.07454545 67.09091 0.56364 0.105455 67.19636 33.59818 66.402 1.5263158 1.82218 
30 0.09 8.181818 0.081818 73.63636 0.074545 0.18 73.81636 36.90818 63.092 1.5671227 1.799973 
40 0.099 9 0.09 81 0.081818 0.261818 81.26182 40.63091 59.369 1.6088565 1.7735604 
50 0.105 9.545455 0.09545455 85.90909 0.09 0.351818 86.26091 43.13045 56.87 1.6631525 1.7320573 
60 0.112 10.18182 0.10181818 91.63636 0.095455 0.447273 92.08364 46.04182 53.958 1.6631525 1.7320573 
120 0.12 10.90906 0.10909091 98.18182 0.101818 0.549091 98.73091 49.36545 50.635 1.6934231 1.7044469 
180 0.05 3.333333 0.03333333 30 0 0 30 15 85 1.760913 1.9294189 
240 0.059 3.933333 0.03933333 35.4 0.033333 0.033333 35.43333 17.71667 82.283 1.248382 1.9153119 
300 0.065 4.333333 0.04333333 39 0.039333 0.072667 39.07267 19.53633 80.464 1.2908431 1.9055998 
360 0.072 4.8 0.048 43.2 0.043333 0.116 43.316 21.658 78.342 1.3356183 1.8939947 
420 0.08 5.333333 0.05333333 48 0.048 0.164 48.164 24.082 75.918 1.3816926 1.8803448 
480 0.085 5.666667 0.05666667 51 0.053333 0.217333 51.21733 25.60867 74.391 1.408387 1.8715223 
520 0.005 5 0.05 45 0 0 45 22.5 77.5 1.3521825 1.8893017 
580 0.003 3 0.03 27 0.05 0.05 27.05 13.525 86.475 1.1311373 1.9368906 
640 0.002 2 0.02 18 0.03 0.08 18.08 9.04 90.96 0.9561684 1.9588505 
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Table 5.12 Dissolution profiles of formulation of F4 
 
Time Absorbance C in 
mcg 
C in V 
made up 
C in 
D.M Loss CLA CDR %CDR 
C%D 
Retained 
Log% CD 
Released 
Log %CD 
Retained 
5 0.059 5.363636 0.0536364 48.27273 0 0 48.27273 24.13636 75.86364 1.3826718 1.88003366 
10 0.068 6.181818 0.0618182 55.63636 0.053636 0.053636 55.69 27.845 72.155 1.4447472 1.85826643 
20 0.084 7.636364 0.0763636 68.72727 0.061818 0.115455 68.84273 34.42136 65.57864 1.5368281 1.85826643 
30 0.091 8.272727 0.0827273 74.45455 0.076364 0.191818 74.64636 37.32318 62.67682 1.5719787 1.79710694 
40 0.1 9.090909 0.0909091 81.81818 0.82727 0.274545 82.09273 41.04636 58.95364 1.6132747 1.7705106 
50 0.11 10 0.1 90 0.090909 0.365455 90.36545 45.18273 54.81727 1.6549724 1.7389174 
60 0.115 10.45455 0.1045455 94.09061 0.1 0.465455 94.55636 47.278181 52.72182 1.67466608 1.72199038 
120 0.121 11 0.11 99 0.104545 0.57 993.57 49.785 50.215 1.6970985 1.70083347 
180 0.057 308 0.038 34.2 0 0 34.2 17.1 82.9 1.2329961 1.91855453 
240 0.067 4.466667 0.0446667 40.2 0.038 0.038 40.238 20.119 79.818 1.3036064 1.90244349 
300 0.075 5 0.05 45 0.044667 0.082667 45.08267 22.54133 77.45867 1.3529796 1.88907002 
360 0.08 5.333333 0.05333333 48 0.05 0.132667 48.13267 24.06633 75.93367 1.3814099 1.88043437 
420 0.085 5.666667 0.0566667 51 0.0533333 0.186 51.186 25.593 74.407 1.4081212 1.87161379 
480 0.089 5.933333 0.0593333 53.4 0.0566667 0.242667 53.64267 26.82133 73.17867 1.4284804 1.86438449 
540 0.009 9 0.09 81 0 0 81 40 60 1.60206 1.77815125 
600 0.0077 0.07 63 0.09 0.09 0.09 63.09 31.45 68.55 1.4976206 1.83600746 
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Table 5.13 Dissolution profiles of formulation of F5 
 
Time Absorbance C in mcg C in V 
made up C in D.M Loss CLA CDR %CDR 
C%D 
Retained 
Log% 
CD 
Released 
Log %CD 
Retained 
5 0.019 1.727273 0.017273 15.54545 0 0 15.54545 7.772727 92.227273 0.890573 1.9648594 
10 0.027 2.454545 0.024545 22.09091 0.017273 0.017273 22.10818 11.05409 88.945909 1.043523 1.949126 
20 0.036 3.272727 0.032727 29.45455 0.024545 0.041818 29.49636 14.74818 85.251818 1.168738 1.9307037 
30 0.05 4.545455 0.045455 40.90909 0.032727 0.074545 40.98364 20.49182 79.508182 1.31158 1.9004118 
40 0.056 5.090909 0.050909 45.81818 0.045455 0.12 45.93818 22.96909 77.030909 1.361144 1.886665 
50 0.08 7.272727 0.072727 65.45455 0.050909 0.170909 65.62545 32.81273 67.187273 1.516042 1.827287 
60 0.082 7.454545 0.074545 67.09091 0.072727 0.243636 67.33455 33.66727 66.332727 1.527208 1.827279 
120 0.085 7.727273 0.07273 69.54545 0.074545 0.318182 69.86364 34.91391 65.068182 .1543221 1.8213687 
180 0.038 2.533333 0.025333 22.8 0 0 22.8 11.4 88.6 1.056905 1.9474337 
240 0.036 2.4 0.024 21.6 0.025333 0.025333 21.62533 10.81267 89.187333 1.033933 1.9503032 
300 0.032 2.13333 0.021333 19.2 0.024 0.049333 19.24933 9.624667 90.375333 0.983386 1.9560499 
360 0.036 2.4 0.024 21.6 0.021333 0.070667 21.67067 10.83533 89.164667 1.034842 1.9501928 
420 0.03 2 0.02 18 0.024 0.094667 18.09467 9.047333 90.952667 0.956521 1.9588154 
480 0.046 3.06667 0.030667 27.6 0.02 0.114667 27.71467 13.85733 86.142667 1.14168 1.9352183 
540 0.005 5 0.05 45 0 0 45 22.5 77.5 1.352183 1.8893017 
600 0.006 6 0.06 54 0.05 0.05 54.05 27.02 72.98 1.431685 1.8632039 
660 0.008 8 0.08 72 0.06 0.06 72.06 36.5 63.95 1.556905 1.8058405 
720 0.006 6 0.06 54 0.08 0.08 54.08 27.75 72.925 1.432568 1.8628764 
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Table 5.14 Dissolution profiles of formulation of F6 
 
Time Absorbance C in mcg C in V 
made up C in D.M Loss CLA CDR %CDR 
C%D 
Retained 
Log% CD 
Released 
Log 
%CD 
Retained 
5 0.048 4.363636 0.43636 39.27273 0 0 39.27273 19.63636 80.364 1.2930611 1.90506 
10 0.058 5.272727 0.052727 47.45455 0.043636 0.043636 47.49818 23.74909 76.251 1.375647 1.882245 
20 0.062 5.636364 0.056364 50.27272 0.052727 0.096364 50.82364 25.41182 74.588 1.4050357 1.87267 
30 0.067 6.090909 0.060909 54.81818 0.056364 0.152727 54.97091 27.48545 72.515 1.4391029 1.860425 
40 0.069 6.272727 0.062727 56.45455 0.060909 0.213636 56.66818 28.33409 71.666 1.4523093 1.855313 
50 0.072 6.545455 0.065455 58.90909 0.062727 0.276364 59.18545 29.59273 70.407 1.471185 1.847618 
60 0.077 7 0.07 63 0.05455 0.341818 63.34182 31.67091 68.329 1.5006605 1.834606 
120 0.081 7.363636 0.073636 66.27273 0.07 0.41818 66.68455 33.34227 66.658 1.5229952 1.823851 
180 0.048 0.851613 0.032 28.8 0 0 28.8 14.4 85.6 1.1583625 1.932474 
240 0.042 0.745161 0.028 25.2 0.032 0.032 35.232 12.61 .87.39 1.1007151 1.941462 
300 0.039 0.691935 0.026 23.4 0.028 0.06 23.46 11.7 88.3 1.0681859 1.945961 
360 0.0367 0.656452 0.024 22.2 0.026 0.086 22.286 11.14 88.86 1.0468852 1.948706 
420 0.042 0.745161 0.028 25.2 0.024 0.11 25.31 12.65 87.35 1.1020905 1.941263 
480 0.05 0.887097 0.033 30 0.028 0.128 30.128 15 85 1.1760913 1.929419 
520 0.007 7 0.07 63 0 0 63 31.54 68.46 1.4988617 1.835437 
600 0.005 5 0.05 45 0.07 0.07 45.07 22.6 77.4 1.3541084 1.888741 
660 0.003 3 0.03 27 0.05 0.12 27.12 13.65 86.35 1.1351327 1.936262 
720 0.002 2 0.02 18 0.03 0.15 18.15 9.16 90.84 0.9618955 1.958277 
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 Post compression evaluation 
In-vitro drug release studies were carried out in dissolution test apparatus type-1 
basket, in 900ml of 0.1 N HC1 for first 2hrs, 900ml of phosphate buffer pH7.4 up to 
6.8 up to 4hrs and drug release was found to be up to 93.3% in 12hrs. Based on the 
results of in-vitro release studies F4 was selected as optimized formulation in this 
formulation HPMC E15 is used 40mg and Eudragit L100 in 60 mg more than this 
amount the drug shows release at the faster rate . due to the various physiochemical 
properties of HPMCE15. , HPMC E 15 LV was added in all five formulations (F1-F6) 
to improve the perfection and quality of the coating. The purpose of incorporation 
HPMC E 15 LV to the coating was to improve the physicochemical property of the 
coating film, such as ductility, toughness and elasticity. (ofori-Kwakye K, Fell JT 
2001) (Yuen KH et al 1993)Such film may provide expected controlled release of the 
drug in the small intestine by offering the increased permeability properties of the 
fluids present in the colon. (Frohoff-Hulsmann et al 1999)
. 
(Chan LW et 
al2005)Coating with polymer solution more than this concentration was found to be 
problematic, and significant tablet agglomeration was experienced during coating 
because of the thermoplasticness and tackiness of the Eudragit coating system.
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Fig 5.13 Drug release profiles of formulations of F1 to F6 
5.5.2 Kinetic release models of optimized formulation 
To analyse the mechanism of the drug release rate kinetics of the mexilrtine 
hydrochloride given in the table 5.15, the data obtained were graphed as 
1) Cumulative percentage drug released v/s time(In-vitro drug release profile) 
2) Cumulative percentage drug released v/s Square root of time (Higuchi’s plots) 
3) Log cumulative percentage drug remaining v/s time (First order release) 
4) Log percentage drug released v/s log time (Peppas plots)(Nish demn 2003) 
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Table 5.14 Kinetics of drug release of R2 value for F4 formulation. 
Model Name K Value R2  value 
Zero order 1.901 0.969 
First Order -0.010 0.977 
Peppas model 0.457 0.990 
Higuchi model 9.697 0.997 
 
 
Fig 5.14 Zero order drug release profiles of optimized formulation 
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Fig 5.15 First order comparative dissolution profiles of optimized formulation 
 
Fig 5.16 Higuchi comparative dissolution profiles of optimized formulation 
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Fig 5.17 Peppas comparative dissolution profiles of optimized formulation 
RELEASE MODEL KINETICS DISCUSSION 
However, the curve fitting investigations of the release profile gave us useful 
insight into the mechanism of drug release from the capsule. The release of the drug 
from the capsule was controlled. The R2 value of the data obtained from the capsule is 
the first Order. The release predicts that the drug follows Higuchi model the value of 
R2 is 0.997. Investigated formulations were having timed-release profile; therefore 
keeping in view all the evolutions, F4 was selected. It was expected such a suitable 
formulation would be useful to achieve the timed-release profile. 
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5.6 Stability studies 
Stability studies were carried out using Thermo lab stability chamber.  After 
4weeks the optimized formulation was tested for physical appearance, drug content 
and DSC.  
Table 5.14 Stability study analysis 
 Parameters  2nd week 4thweek 
Physical Appearance No Change No Change 
Drug content 90.3% 93.3% 
 
 
Fig 5.18 DSC graph of formulation IV after stability studies 
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Discussion:   
Granules were kept for accelerated stability study at 40±2◦C and 75±5% RH 
for 4 weeks in stability chamber. After a period of 4 weeks, the samples were 
observed for any physical parameters, drug content and DSC. It was observed that 
there is no change in appearance, drug content and DSC. 
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6. SUMMARY  
A Timed- release delivery system for Mexiletine Hydrochloride was designed 
to increase its patient compliance by using a suitable polymer. Compared to oral 
conventional delivery system, the frequency of dosing may be less.  
The various pre formulation studies like melting point determination, 
solubility, and calibration curve of the drug by UV spectroscopy and physico - 
chemical characteristics of drug have been studied. 
The results of all these parameters are tabulated and depicted graphically in 
the result and discussion section. 
Six formulations were prepared by using same drug and polymer in different 
ratios. The granules were prepared by using the wet granulation technique and were 
subjected to evaluation of granular properties like angle of repose, bulk density, 
compressibility index and Hausner’s ratio. 
Evaluation parameters viz. bulk density, angle of repose, drug content  Carr’s 
compressibility index was found to be less than 20% for all the formulations 
indicating that the powder is compressible. Bulk density and true densities were found 
to be <1 for all formulation powders.were within acceptable limits for all six 
formulation. 
Results of in-vitro release using USP dissolution apparatus indicated that the 
drug release of formulation F4 is satisfactory and others it was found to be 50% - 
93.3% for 12 hrs respectively. 
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The results of kinetic drug release of formulation F4 in the R2 value was 
highest for Higuchi model. 
Stability study for the granules at 40±2◦C and 75±5% RH for 4 weeks in 
stability chamber. It was observed that there is no change in appearance, drug content 
and DSC. 
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CONCLUSION 
The conclusions drawn from the present investigation were given below 
 Suitable analytical method based on UV-Visible spectrophotometer was 
developed for Mexiletine Hydrochloride.  262 nm was identified as an  in 
purified water. 
 Timed-release capsules of Mexiletine HC1 were successfully prepared using                           
Lactose, HPMC E15 and Eudragit L 100 by wet granulation method. 
 The timed-release capsules were evaluated for pharmacopoeial and non-
Pharmacopoeial (industry specified) tests. Based on the results batch F4 was 
identified as better formulations amongst all formulations for delivering the drug 
in a pulsatile manner. 
 Mexiletine HC1 release from the developed formulations has been observed to 
be directly proportional to the amount of polymer present in capsules. Capsules 
of batch F4 passed all official and unofficial quality control tests. 
 Data obtained from kinetic treatment revealed F4 formulation follow Higuchi 
model. 
 Accelerated stability developed formulations were found to be stable. 
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